<SEC-DOCUMENT>0001213900-25-094711.txt : 20251001
<SEC-HEADER>0001213900-25-094711.hdr.sgml : 20251001
<ACCEPTANCE-DATETIME>20251001163026
ACCESSION NUMBER:		0001213900-25-094711
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20250929
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251001
DATE AS OF CHANGE:		20251001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silo Pharma, Inc.
		CENTRAL INDEX KEY:			0001514183
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				462137136
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41512
		FILM NUMBER:		251365029

	BUSINESS ADDRESS:	
		STREET 1:		677 N. WASHINGTON BLVD
		CITY:			SARASOTA
		STATE:			FL
		ZIP:			34236
		BUSINESS PHONE:		(718) 400-9031

	MAIL ADDRESS:	
		STREET 1:		677 N. WASHINGTON BLVD
		CITY:			SARASOTA
		STATE:			FL
		ZIP:			34236

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Uppercut Brands, Inc.
		DATE OF NAME CHANGE:	20190808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Point Capital, Inc.
		DATE OF NAME CHANGE:	20130130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gold Swap Inc
		DATE OF NAME CHANGE:	20110301
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0259464-8k_silo.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:SILO="http://silopharma.com/20250929">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_SILO_silopharma.com_20250929 -->
<!-- Field: Set; Name: xdx; ID: xdx_043_20250929_20250929 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001514183 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000004" name="dei:EntityCentralIndexKey">0001514183</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="silo-20250929.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001514183</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-29</xbrli:startDate>
        <xbrli:endDate>2025-09-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90B_edei--DocumentType_c20250929__20250929_zstFM8leEyV6"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_903_edei--DocumentPeriodEndDate_c20250929__20250929_zyMmf6DR3Rd5"><ix:nonNumeric contextRef="AsOf2025-09-29" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 29, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20250929__20250929_zoMmOZlbXYfl"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000011" name="dei:EntityRegistrantName">Silo Pharma, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250929__20250929_zFlJ0JaFsBS7"><ix:nonNumeric contextRef="AsOf2025-09-29" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityFileNumber_c20250929__20250929_z7geFjBJquh7"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000013" name="dei:EntityFileNumber">001-41512</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20250929__20250929_zYIFaooyijwd"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-3046338</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br/>
of incorporation)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20250929__20250929_zkLitgaubz0j"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000015" name="dei:EntityAddressAddressLine1">677 N. Washington Boulevard</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20250929__20250929_zwJII6VlEp24"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000016" name="dei:EntityAddressCityOrTown">Sarasota</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20250929__20250929_zUAXm9UejYP4"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000017" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span></b></p></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressPostalZipCode_c20250929__20250929_zeEEZHunLfKd"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000018" name="dei:EntityAddressPostalZipCode">34236</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_908_edei--CityAreaCode_c20250929__20250929_zkQmiaBu6G88"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000019" name="dei:CityAreaCode">718</ix:nonNumeric></span>) <span id="xdx_905_edei--LocalPhoneNumber_c20250929__20250929_zy1FMqoaqiq8"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000020" name="dei:LocalPhoneNumber">400-9031</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A<br/>
</b>(Former name or former address, if changed since last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i>
General Instruction A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--WrittenCommunications_c20250929__20250929_zJM7cERZWlM8"><ix:nonNumeric contextRef="AsOf2025-09-29" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SolicitingMaterial_c20250929__20250929_zmfED8p7iRz9"><ix:nonNumeric contextRef="AsOf2025-09-29" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--PreCommencementTenderOffer_c20250929__20250929_zOc4Z1t3RRW3"><ix:nonNumeric contextRef="AsOf2025-09-29" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20250929__20250929_zSnmefuKLQOi"><ix:nonNumeric contextRef="AsOf2025-09-29" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Rule 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20250929__20250929_zez3E8bq1Un1"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000025" name="dei:Security12bTitle">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20250929__20250929_zZ5IlGQDwaD"><ix:nonNumeric contextRef="AsOf2025-09-29" id="Fact000026" name="dei:TradingSymbol">SILO</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20250929__20250929_zRW7aYel19Gl"><ix:nonNumeric contextRef="AsOf2025-09-29" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20250929__20250929_z3IjB9XQbSV5"><ix:nonNumeric contextRef="AsOf2025-09-29" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 29, 2025, Silo
Pharma, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain
institutional investors, pursuant to which the Company agreed to sell to such investors 2,857,143 shares (the &#8220;Shares&#8221;) of
common stock, par value $0.0001 per share of the Company (the &#8220;Common Stock&#8221;) at a purchase price of $0.875 per Share (the
&#8220;Offering&#8221;). The Shares were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-276658),
which was declared effective by the Securities and Exchange Commission on January 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the sale
of the Shares pursuant to the Purchase Agreement in a private placement, for each Share purchased by the investors, such investors received
from the Company an unregistered warrant (the &#8220;Warrants&#8221;) to purchase one share of Common Stock (the &#8220;Warrant Shares&#8221;).
The Warrants have an exercise price of $0.75 per share, are exercisable immediately upon issuance and will expire five years from the effective date of a registration
statement registering for resale the underlying Warrant Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of the sales of
these securities under the Purchase Agreement took place on October 1, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The gross proceeds from the
Offering were approximately $2.5 million, prior to deducting placement agent&#8217;s fees and other offering expenses payable by the
Company. The Company intends to use the net proceeds from the Offering for working capital and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants and the Warrant
Shares were sold without registration under the Securities Act of 1933 (the &#8220;Securities Act&#8221;) in reliance on the exemptions
provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities
Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The representations, warranties
and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to the Purchase Agreement. In addition,
such representations, warranties and covenants (i) are intended as a way of allocating the risk between the parties to the Purchase Agreement
and not as statements of fact, and (ii) may apply standards of materiality in a way that is different from what may be viewed as material
by stockholders of, or other investors in, the Company. Accordingly, the Purchase Agreement is included with this filing only to provide
investors with information regarding the terms of the transaction, and not to provide investors with any other factual information regarding
the Company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the
Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 5, 2025, the
Company entered into an engagement agreement with H.C. Wainwright &amp; Co., LLC, as exclusive placement agent (the &#8220;Placement
Agent&#8221;) as amended on each of April 8, 2025, May 6, 2025 and September 29, 2025, pursuant to which the Placement Agent agreed
to act as placement agent on a reasonable &#8220;best efforts&#8221; basis in connection with the Offering. The Company agreed to
pay the Placement Agent an aggregate cash fee equal to 7.5% of the gross proceeds from the sale of securities in the Offering and a
management fee equal to 1.0% of the gross proceeds raised in the Offering. The Company also agreed to <span style="background-color: white">issue
the Placement Agent (or its designees) warrants (the &#8220;Placement Agent Warrants&#8221;) </span>to purchase up to 7.5% of the
aggregate number of Shares sold in the Offering, or warrants to purchase up to 214,285 shares of Common Stock, at an exercise price
equal to 125% of the offering price per Share, or $1.0938 per share. The Placement Agent Warrants are exercisable immediately upon
issuance for a period of five years following the commencement of the sales pursuant to the Offering. In addition, the Company
agreed to reimburse the Placement Agent $25,000 for non-accountable expenses, $50,000 for legal expenses and other out-of-pocket
expenses and $15,950 for clearing fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms of
the Purchase Agreement and subject to certain exceptions as set forth in the Purchase Agreement, from the date of the Purchase
Agreement until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall issue, enter into any
agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents (as
defined in the Purchase Agreement). In addition, until one (1) year after the Closing Date, the Company is prohibited from
entering into a Variable Rate Transaction (as defined in the Purchase Agreement), subject to certain limited exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Company has agreed to file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing
for the resale of the Warrant Shares (the &#8220;Resale Registration Statement&#8221;) within 15 calendar days of the date of the Purchase
Agreement (the &#8220;Filing Date&#8221;), and to use commercially reasonable efforts to cause the Resale Registration Statement to be
declared effective by the SEC within 75 calendar days following the date of the Filing Date and to keep the Resale Registration Statement
effective at all times until the Holders no longer own any Warrants or Warrant Shares.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
of the Warrant, the Placement Agent Warrant and Purchase Agreement are not complete and are qualified in their entirety by reference to
the full text of the form of Warrant, form of Placement Agent Warrant, and form of Purchase Agreement, copies of which are filed
as Exhibits 4.1, 4.2, and 10.1, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The legal opinion and consent
of Sheppard, Mullin, Richter &amp; Hampton LLP relating to the validity of the securities issued in the Offering is filed herewith as
Exhibit 5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reference is made to the disclosure
under Item 1.01 above which is hereby incorporated in this Item 3.02 by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants and the Placement
Agent Warrants and the shares issuable upon exercise of the Warrants and Placement Agent Warrants have not been registered under the Securities
Act, or the securities laws of any state, and are being offered and sold in reliance
on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01</b>&#160;<b>Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 30, 2025, the
Company issued a press release announcing the pricing of the Offering.&#160;A copy of the press release is furnished as Exhibit 99.1 to
this Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 1, 2025, the Company
issued a press release announcing the closing of the Offering. A copy of the press release is furnished as Exhibit 99.2 to this Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea025946401ex4-1_silo.htm">Form of Warrant</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea025946401ex4-2_silo.htm">Form of Placement Agent Warrant</a></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea025946401ex5-1_silo.htm">Opinion of Sheppard, Mullin, Richter &amp; Hampton LLP</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea025946401ex10-1_silo.htm">Form of Securities Purchase Agreement</a></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea025946401ex99-1_silo.htm">Press release of Silo Pharma, Inc. dated September 30, 2025</a></span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea025946401ex99-2_silo.htm">Press release of Silo Pharma, Inc. dated October 1, 2025</a></span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: #CCEEFF">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The schedules (and similar attachments) to this exhibit have been
    omitted from this filing pursuant to Item 601(b)(10) of&#160;Regulation S-K.&#160;The&#160;Company agrees to furnish a supplemental
    copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request</p></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SILO PHARMA, INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 37%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 1, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Eric Weisblum</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric Weisblum</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">-3-</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6La6bOHCXjiniFBki3haXSXFrRlp/9ki+pXVDDIGQnPOdCDERa1rpBhnOy7KAI7ZdoxxCiTUymgt6R7bZpuBniVdtHSvjhvUHZuQZ9EwyjZS/D86HtlilIBfhTIbxHGSSRjEcdiL46hmZWldonFYNKFPBgaljjU5xPyYc1YsMtf3w6YRsNZkUoqkc5TfE0uft6aGexDcLRZGJYDJUINZM98678pdD8yUhb7D17+xI/zv4AMtqSlw= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea025946401ex4-1_silo.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT A-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY NOR THE
SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Silo
Pharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>Warrant Shares: _______</TD>
    <TD STYLE="text-align: right">Initial Exercise Date: September ___, 2025</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on the date that is
five (5) years from the effective date of a resale registration statement registering the resale by the Holder of all of the Warrant Shares
issued and issuable upon exercise of this Warrant (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and
purchase from Silo Pharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment
hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant
shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated September ___, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified
in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day
of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$0.75</B>, subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part,
at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares
equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD><TD STYLE="text-align: justify; width: 0.2in">=</TD>
                                                                                <TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in
Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock
on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo;
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such
Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after
the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(B)</TD><TD STYLE="text-align: justify; width: 0.2in">=</TD>
                                                                                <TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(X)</TD><TD STYLE="text-align: justify; width: 0.2in">=</TD>
                                                                                <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The
Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&ldquo;OTCQB&rdquo;) or the OTCQX Best
Market (&ldquo;OTCQX&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and
if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;Pink Market&rdquo;) operated by the OTC Markets, Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)
<U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.   <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant
to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s
share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to
such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading
Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of
(i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such
Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a
transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
&ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.   <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.   <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.   <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.   <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.   <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.   <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request
of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be [4.99%] [9.99%] of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this
Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the
Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than
50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company&rsquo;s control,
including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor
Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this
Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction,
whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given
the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>,
that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders
of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following
such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant
based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation
of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S.
Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction
and the Termination Date, (B) an expected volatility equal to the 100 day volatility as obtained from the HVT function on Bloomberg (determined
utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered
in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction; (D) a remaining
option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the
Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available
funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation
of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and
substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of
shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this
Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant
and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company,
may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the
obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company
and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt,
the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient
authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the
Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)   <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.   <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.   <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the
Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)   <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)   <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)   <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)   <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)   <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)   <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)   <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)   <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)   <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)   <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)   <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)   <U>Amendment</U>.
Other than Section 2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may be modified or amended
or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)   <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)   <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="text-transform: uppercase"><B>Silo Pharma, Inc.</B></FONT> &nbsp; &nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD>Title: &nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: Silo
Pharma, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(1)   The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(2)   Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> &#9744; in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"> &#9744; if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(3)   Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(4) <U>Accredited Investor</U>.
The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 50%; text-align: justify; font-size: 10pt"><U></U>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; font-size: 10pt"><U></U>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; font-size: 10pt">(Please Print) </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD> Email Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Signature:__________________________<U> </U></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Address:___________________________<U> </U></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ea025946401ex4-2_silo.htm
<DESCRIPTION>FORM OF PLACEMENT AGENT WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY NOR THE
SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Silo
Pharma, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="text-align: right; width: 40%; font-size: 10pt">Initial Exercise Date: October 1, 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PLACEMENT AGENT COMMON
STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, <FONT STYLE="font-variant: small-caps">_____________</FONT>
or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00
p.m. (New York City time) on September 29, 2030 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase
from Silo Pharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder,
the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be
equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and
between the Company and H.C. Wainwright &amp; Co., LLC, dated as of March 5, 2025, as amended on April 8, 2025, May 6, 2025 and September
29, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated September 29, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within
the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section
2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified
in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day
of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$1.0938</B>, subject to adjustment hereunder (the
&ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part,
at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares
equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in; text-align: left">(A) = </TD><TD STYLE="text-align: justify">as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99pt; text-align: justify; text-indent: -27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.35in; text-align: left">(B) = </TD><TD STYLE="text-align: justify">the Exercise
Price of this Warrant, as adjusted hereunder; and</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">(X) =</TD><TD STYLE="text-align: justify">the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if the OTCQB Venture Market (&ldquo;OTCQB&rdquo;) or the OTCQX Best
Market (&ldquo;OTCQX&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and
if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;Pink Market&rdquo;) operated by the OTC Markets, Inc.
(or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> d) <U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant
to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s
share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to
such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading
Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement
Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;).
Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of
(i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice
of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such
Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a
transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein,
&ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may
rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request
of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of
the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held
by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise, other
than cash (including, without limitation, any distribution of stock or other securities, property or options by way of a dividend, spin
off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than
50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company&rsquo;s control,
including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor
Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this
Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction,
whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given
the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <U>provided</U>, <U>further</U>,
that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders
of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following
such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant
based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation
of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S.
Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction
and the Termination Date, (B) an expected volatility equal to the 100 day volatility as obtained from the HVT function on Bloomberg (determined
utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated
Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered
in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction; (D) a remaining
option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the
Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available
funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation
of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and
substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction
and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced
by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of
shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately
prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder.
Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this
Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant
and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company,
may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the
obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company
and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt,
the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient
authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the
Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to
such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice
or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the
Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered to
the address of the Holder in the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
Other than Section 2(e) above and this Section 5(l), which may not be amended, modified or waived, this Warrant may be modified or amended
or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="3" STYLE="text-transform: uppercase; text-align: left"><B>Silo Pharma, Inc.</B></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD COLSPAN="2" STYLE="text-transform: uppercase; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">By:&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-transform: uppercase; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60%">&nbsp;</TD><TD STYLE="text-align: left; width: 3%">&nbsp;</TD><TD STYLE="text-align: justify; width: 5%">Name:</TD>
                                                       <TD STYLE="text-transform: uppercase; text-align: justify; width: 32%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Title:</TD>
                                                       <TD STYLE="text-transform: uppercase; text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">Silo Pharma, Inc.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(4) <U>Accredited Investor</U>.
The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.25in"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name:</P></TD>
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><U> </U>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><U> </U>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address:</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Signature: ______________________<U> </U></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Address: ______________________<U> </U></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>ea025946401ex5-1_silo.htm
<DESCRIPTION>OPINION OF SHEPPARD, MULLIN, RICHTER & HAMPTON LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="4" STYLE="width: 70%; padding-top: 3.3pt; padding-right: 6.95pt"><IMG SRC="ex5-1_001.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-top: 3.3pt; padding-right: 6.95pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sheppard, Mullin, Richter &amp; Hampton LLP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">30 Rockefeller Plaza</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 6.95pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, New York 10112-0015</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">212.653.8700 main</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212.653.8701 fax</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.sheppardmullin.com</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">October 1, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B><U>VIA EDGAR</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Silo Pharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">677 N. Washington Boulevard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Sarasota, FL 34236</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">Re: <U>Registration Statement on Form S-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We have acted as counsel to Silo
Pharma, Inc. (the &ldquo;Company&rdquo;), a Nevada corporation in connection with the offering for sale of 2,857,143 shares (the &ldquo;Shares&rdquo;)
of common stock of the Company, par value $0.0001 per share (the &ldquo;Common Stock&rdquo;), pursuant to the Registration Statement (as
defined below) and the Prospectus (as defined below). Unless defined herein, capitalized terms have the meanings given to them in that
certain Securities Purchase Agreement (the &quot;Securities Purchase Agreement&quot;), dated September 29, 2025, by and among the Company
and the purchasers identified on the signature pages thereto (the &ldquo;Purchasers&rdquo;), relating to the issuance and sale by the
Company of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">This opinion is being furnished in
accordance with the requirements of Item 601(b)(5)(i) of Regulation S-K. In connection with this opinion, we have reviewed and relied
upon the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the Registration Statement on Form S-3 (File No. 333-276658) initially filed with
the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) on January 23, 2024 under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;) (including any documents incorporated by reference therein, the &ldquo;Registration Statement,&rdquo;
and the related prospectus included in such Registration Statement at the time it became effective on January 30, 2024 (including any
documents incorporated by reference therein, the &ldquo;Base Prospectus&rdquo;));</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the prospectus supplement, which includes the Base Prospectus, filed on October
1, 2025 pursuant to Rule 424(b) under the Securities Act, which is referred to as the &ldquo;Prospectus&rdquo;;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the Securities Purchase Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the Articles of Incorporation of the Company in effect on the date hereof;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the Bylaws of the Company in effect on the date hereof;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">the resolutions of the Board of Directors of the Company, adopted on September 29,
2025 and the resolutions of the Pricing Committee of the Board of Directors of the Company dated September 29, 2025 authorizing/ratifying
the execution and delivery of the Securities Purchase Agreement, the issuance and sale of the Shares and the preparation and filing of
the Prospectus, and other actions with regard thereto; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">such other documents, records, certificates, memoranda and other instruments as
we deem necessary as a basis for this opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In our examination, we have assumed
the genuineness of all signatures, including endorsements, the legal capacity and competency of all natural persons, the authenticity
of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as facsimile, electronic,
certified or photocopy, and the authenticity of the originals of such copies. As to any facts relevant to the opinions stated herein that
we did not independently establish or verify, we have relied upon statements and representations of officers and other representatives
of the Company and others and of public officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Based upon the foregoing and subject
to the qualifications and assumptions stated herein, we are of the opinion that the Shares have been duly authorized by all requisite
corporate action on the part of the Company under the Nevada Revised Statutes (the &ldquo;NRS&rdquo;) and, when the Shares are delivered
to and paid for by the Purchasers in accordance with the terms of the Securities Purchase Agreement and when evidence of the issuance
thereof is duly recorded in the Company&rsquo;s books and records, the Shares will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We hereby consent to the filing of
this opinion letter as an exhibit to the Company&rsquo;s Current Report on Form 8-K being filed on the date hereof and incorporated by
reference into the Registration Statement. We also hereby consent to the reference to our firm under the caption &ldquo;Legal Matters&rdquo;
in the Prospectus. In giving this consent, we do not admit that we are within the category of persons whose consent is required under
Section 7 of the Securities Act, the rules and regulations of the Commission promulgated thereunder or Item 509 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We express no opinion as to matters governed
by any laws other than the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We disclaim any obligation to advise
you of facts, circumstances, events or developments that hereafter may be brought to our attention and that may alter, affect or modify
the opinion expressed herein. Our opinion is expressly limited to the matters set forth above and we render no opinion, whether by implication
or otherwise, as to any other matters relating to the Company or the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60%"></TD><TD STYLE="text-align: justify; width: 40%">Respectfully submitted,</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">SHEPPARD, MULLIN, RICHTER &amp; HAMPTON LLP</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.95pt 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ea025946401ex10-1_silo.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: capitalize; text-align: right; text-indent: -0.5in"><B>Exhibit
10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><B>SECURITIES
PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-transform: uppercase; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of September ___, 2025, between Silo Pharma, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to (i) an effective registration statement under the Securities Act (as defined
below) as to the Shares, the Pre-Funded Warrants and Pre-Funded Warrant Shares and (ii) an exemption from the registration requirements
of Section 5 of the Securities Act contained in Section 4(a)(2) thereof and/or Regulation D thereunder as to the Common Warrants and the
Common Warrant Shares, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE I.</B><BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following
terms have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Acquiring Person</U>&rdquo;
shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof (or the second (2<SUP>nd</SUP>) Trading Day following the date hereof if this Agreement is signed on a day
that is not a Trading Day or after 4:00 p.m. (New York City time) and before midnight (New York City time) on a Trading Day).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrants</U>&rdquo; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with
Section 2.2(a) hereof, which Common Warrants shall be immediately exercisable on issuance and have a term of exercise equal to five (5)
years from the effective date of a resale registration statement registering the resale by the Purchasers of all of the Common Warrant
Shares issued and issuable upon exercise of the Common Warrants, in the form of <U>Exhibit A-1</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Common Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Sheppard, Mullin, Richter &amp; Hampton LLP, with offices located at 30 Rockefeller Plaza, New York, NY 10112-0015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock, options, restricted stock units or other securities to employees,
officers, directors or independent contractors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a
majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established
for such purpose for services rendered to the Company, provided that such securities issued to independent contractors are issued as &ldquo;restricted
securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement
in connection therewith during the prohibition period in Section 4.11(a) herein, (b) securities upon the exercise or exchange of or conversion
of any Securities issued hereunder, warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and
any securities upon exercise of warrants to the Placement Agent and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c)
securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company,
provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a)
herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide
to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $0.875, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement, provided that the purchase price per Pre-Funded
Warrant shall be the Per Share Purchase Price minus $0.0001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means H.C. Wainwright &amp; Co., LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrants</U>&rdquo; means, collectively, the pre-funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately and shall expire when exercised in full, in the
form of <U>Exhibit A-2</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission
and delivered by the Company to each Purchaser at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission file No. 333-276658 which registers the sale of the Shares,
the Pre-Funded Warrants and the Pre-Funded Warrant Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants and Pre-Funded Warrants purchased
hereunder as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds (minus, if applicable, a Purchaser&rsquo;s aggregate exercise
price of the Pre-Funded Warrants, which amounts shall be paid as and when such Pre-Funded Warrants are exercised).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York
Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means West Coast Stock Transfer, Inc., the current transfer agent of the Company, with a mailing address of 721 N. Vulcan
Ave. Suite 106, Encinitas, CA 92024 and a email address of fbrickell@wcsti.com, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.11(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&ldquo;OTCQB&rdquo;) or the OTCQX
Best Market (&ldquo;OTCQX&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or
OTCQX and if prices for the Common Stock are then reported in the Pink Open Market (&ldquo;Pink Market&rdquo;) operated by OTC Markets,
Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the
Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Warrants and the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means, collectively, the Common Warrant Shares and the Pre-Funded Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE II.</B><BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $2,500,001 of Shares and Common Warrants; <U>provided</U>,
<U>however</U>, that to the extent that a Purchaser determines, in its sole discretion, that such Purchaser (together with such Purchaser&rsquo;s
Affiliates, and any Person acting as a group together with such Purchaser or any of such Purchaser&rsquo;s Affiliates) would beneficially
own in excess of the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, in lieu of purchasing Shares, such Purchaser
may elect to purchase Pre-Funded Warrants in such manner to result in the same aggregate purchase price being paid by such Purchaser to
the Company. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 4.99% (or, with respect to each Purchaser, at the election of
such Purchaser at Closing, 9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance
of the Securities on the Closing Date. In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser.
Each Purchaser&rsquo;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser shall be made available
for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee. The Company shall deliver to each Purchaser its
respective Shares and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items
set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3,
the Closing shall take place remotely by electronic transfer of the Closing documentation. Notwithstanding anything herein to the contrary,
if at any time on or after the time of execution of this Agreement by the Company and an applicable Purchaser, through, and including
the time immediately prior to the Closing (the &ldquo;<U>Pre-Settlement Period</U>&rdquo;), such Purchaser sells to any Person all, or
any portion, of the Shares to be issued hereunder to such Purchaser at the Closing (collectively, the &ldquo;<U>Pre-Settlement Shares</U>&rdquo;),
such Purchaser shall, automatically hereunder (without any additional required actions by such Purchaser or the Company), be deemed to
be unconditionally bound to purchase, and the Company shall be deemed to be unconditionally bound to sell, such Pre-Settlement Shares
at the Closing; provided, that the Company shall not be required to deliver any Pre-Settlement Shares to such Purchaser prior to the Company&rsquo;s
receipt of the purchase price of such Pre-Settlement Shares hereunder; and provided further that the Company hereby acknowledges and agrees
that the forgoing shall not constitute a representation or covenant by such Purchaser as to whether or not during the Pre-Settlement Period
such Purchaser shall sell any shares of Common Stock to any Person and that any such decision to sell any shares of Common Stock by such
Purchaser shall solely be made at the time such Purchaser elects to effect any such sale, if any. Unless otherwise directed by the Placement
Agent, settlement of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing
Date, the Company shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly
to the account(s) at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly
electronically deliver such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing
firm) by wire transfer to the Company). Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Pre-Funded
Warrants) delivered on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered at any time after the time
of execution of this Agreement, the Company agrees to deliver the Pre-Funded Warrant Shares subject to such notice(s) by 4:00 p.m. (New
York City time) on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Pre-Funded Warrants)
for purposes hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>this Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>subject to Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead
and executed by the Chief Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv) subject to Section
2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an expedited basis via
The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) Shares equal to such Purchaser&rsquo;s
Subscription Amount divided by the Per Share Purchase Price (minus the number of shares of Common Stock issuable upon exercise of such
Purchaser&rsquo;s Pre-Funded Warrant, if applicable), registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v) a Common Warrant
registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&rsquo;s
Shares and Pre-Funded Warrant Shares initially issuable upon exercise of the Pre-Funded Warrants, if applicable, with an exercise price
equal to $0.75, subject to adjustment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi) for each Purchaser
of Pre-Funded Warrants pursuant to Section 2.1, a Pre-Funded Warrant registered in the name of such Purchaser to purchase up to a number
of shares of Common Stock equal to the portion of such Purchaser&rsquo;s Subscription Amount applicable to Pre-Funded Warrant divided
by the Per Share Purchase Price minus $0.0001, with an exercise price equal to $0.0001, subject to adjustment therein; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) On or
prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>this Agreement duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>such Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement
with the Company or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)   The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects)
on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in
which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality,
in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have
been performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being
met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein
(unless as of a specific date therein in which case they shall be accurate in all respects or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>there shall have been no Material Adverse Effect with respect to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE III.</B><BR>
REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Representations and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to
each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns,
directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of
the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of
preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the
Subsidiaries or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Organization and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any
Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or
other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not
have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in
any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material
Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking
to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and
the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection
herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which
it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms
hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with
its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents
to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and
thereby do not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or
articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an
event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties
or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by
which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any
property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give
any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) application(s)
to each applicable Trading Market for the listing of the Shares and Warrant Shares for trading thereon in the time and manner required
thereby, and (iv) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities
laws (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Warrant Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free
and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum number of
shares of Common Stock issuable pursuant to this Agreement and the Warrants. The Company has prepared and filed the Registration Statement
in conformity with the requirements of the Securities Act, which became effective on&nbsp;January 30, 2024, including the Prospectus,
and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration Statement is effective
under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or
preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to
the knowledge of the Company, are threatened by the Commission. The Company, if required by the rules and regulations of the Commission,
shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any amendments thereto
became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto conformed
and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading;
and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement thereto was issued
and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities Act and did not and
will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The Company was at the time of the filing of the Registration
Statement eligible to use Form S-3. The Company is eligible to use Form S-3 under the Securities Act and it meets the transaction requirements
with respect to the aggregate market value of securities being sold pursuant to this offering and during the twelve (12) months prior
to this offering, as set forth in General Instruction I.B.6 of Form S-3.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Capitalization</U>. The capitalization of the Company as of the date hereof is as set forth in the SEC Reports. Except as set
forth in the SEC Reports, the Company has not issued any capital stock since its most recently filed periodic report under the Exchange
Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s stock option plans, the issuance of shares
of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has
any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated
by the Transaction Documents. Except as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there
are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities,
rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire,
any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital
stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common
Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company
or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon
an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary
that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the
Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any
stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding
shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance
with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar
rights to subscribe for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements
with respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among
any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the
one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and
the Prospectus Supplement, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received
a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their
respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act,
as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements
of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations
of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance
with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;),
except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements
may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and
its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Material Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements
included within the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has
had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event,
liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect
to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that
would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made
that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Litigation</U>. Except as set forth in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or
investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth in the SEC Reports, (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if
there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any
Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company,
there is not pending or contemplated, any investigation by the Commission involving the Company or, to the Company&rsquo;s knowledge,
any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo;
employees is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the
Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that
their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and
foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours,
except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compliance</U>. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under),
nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Environmental Laws</U>.&#9;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign
laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface
or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants,
or toxic or hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise
relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials,
as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters,
orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;);
(ii) have received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective
businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the
SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect
(&ldquo;<U>Material Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to
the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned
by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which
is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Intellectual Property</U>. The Company and the Subsidiaries, have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC
Reports and which the failure to so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property
Rights has expired, terminated or been abandoned, or, except as would not, individually or in the aggregate, have a Material Adverse Effect,
is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any
Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of
a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except
as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their
intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged.
Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as
and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without
a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Transactions With Affiliates and Employees</U>. Except as set forth in the SEC Reports, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer,
director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Sarbanes-Oxley; Internal Accounting Controls</U>. Except as set forth in the SEC Reports, the Company and the Subsidiaries are
in compliance with any and all applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are effective as of the date
hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof
and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the Commission&rsquo;s rules and forms. The Company&rsquo;s certifying officers have evaluated
the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by
the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented
in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of
the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been
no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries
that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company
and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Fees</U>. Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Registration Rights</U>. Except as set forth in the SEC Reports, no Person has any right to cause the Company or any Subsidiary
to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice
from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance
with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in
the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current
in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Application of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents)
or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the
Company&rsquo;s issuance of the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their
agents or counsel with any information that it believes constitutes or might constitute material, non-public information which is not
otherwise disclosed in the Prospectus Supplement. The Company understands and confirms that the Purchasers will rely on the foregoing
representation in effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company
to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby is
true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated
by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in
the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser
makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically
set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Integrated Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any
offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the
Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration
of the Common Warrants or Common Warrant Shares under the Securities Act, or (ii) any applicable shareholder approval provisions of any
Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets
exceeds the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on
its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking
into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or
circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws
of any jurisdiction within one year from the Closing Date. The SEC Reports set forth as of the date hereof all outstanding secured and
unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes
of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of $50,000
(other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $50,000 due under leases
required to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Tax Status</U>. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result
in a Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount
claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for
any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Accountants</U>. The Company&rsquo;s accounting firm is set forth in the SEC Reports. To the knowledge and belief of the Company,
such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its opinion with
respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year ending December 31, 2025.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> <U>Acknowledgment Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the
Purchasers is acting solely in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each
Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based solely on
the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff) <FONT STYLE="text-decoration-style: double"><U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(f) and 4.13 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked
by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company,
or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified term; (ii)
past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo;
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of
the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to
which any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and
(iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. </FONT>The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities
at various times during the period that the Securities are outstanding, including, without limitation, during the periods that the value
of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce
the value of the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being conducted.
The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Regulation M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company
to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with
the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;)
under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured,
packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical
Product</U>&rdquo;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by
the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration,
investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure
to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation)
against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter
or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and
promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws
or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical
hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or
any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its
Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and
which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company
have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The
Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product
proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing
any product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Stock Option Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i)
in accordance with the terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market
value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted
under the Company&rsquo;s stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no
Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with,
the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results
or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s
or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware, software, data (including the data of its respective
customers, employees, suppliers, vendors and, to the Company&rsquo;s knowledge, any third party data maintained by or on behalf of it),
equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been
notified of, and has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other
compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable laws or statutes
and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies
and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data
from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material
Adverse Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain
and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and
Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards
and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compliance with Data Privacy Laws</U>. (i)&nbsp;The Company and the Subsidiaries are, and at all times during the last three
(3) years were, in material compliance with all applicable state, federal and foreign data privacy and security laws and regulations,
including, without limitation, the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively,
&ldquo;<U>Privacy Laws</U>&rdquo;); (ii)&nbsp;the Company and the Subsidiaries have in place, comply with, and take appropriate steps
reasonably designed to ensure compliance with their policies and procedures relating to data privacy and security and the collection,
storage, use, disclosure, handling and analysis of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii)&nbsp;the
Company provides accurate notice of its applicable Policies to its customers, employees, third party vendors and representatives as required
by the Privacy Laws; and (iv)&nbsp;applicable Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy
practices relating to its subject matter, and do not contain any material omissions of the Company&rsquo;s then-current privacy practices,
as required by Privacy Laws.&nbsp;&ldquo;<U>Personal Data</U>&rdquo; means (i)&nbsp;a natural person&rsquo;s name, street address, telephone
number, email address, photograph, social security number, bank information, or customer or account number; (ii)&nbsp;any information
which would qualify as &ldquo;personally identifying information&rdquo; under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal
data&rdquo; as defined by GDPR; and (iv)&nbsp;any other piece of information that allows the identification of such natural person, or
his or her family, or permits the collection or analysis of any identifiable data related to an identified person&rsquo;s health or sexual
orientation. (i)&nbsp;None of such disclosures made or contained in any of the Policies have been inaccurate, misleading, or deceptive
in violation of any Privacy Laws and (ii)&nbsp;the execution, delivery and performance of the Transaction Documents will not result in
a breach of any Privacy Laws or Policies. Neither the Company nor the Subsidiaries (i)&nbsp;to the knowledge of the Company, has
received written notice of any actual or potential liability of the Company or the Subsidiaries under, or actual or potential violation
by the Company or the Subsidiaries of, any of the Privacy Laws; (ii)&nbsp;is currently conducting or paying for, in whole or in part,
any investigation, remediation or other corrective action pursuant to any regulatory request or demand pursuant to any Privacy Law; or
(iii)&nbsp;is a party to any order, decree, or agreement by or with any court or arbitrator or governmental or regulatory authority that
imposed any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;<U>Federal Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance
with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering
Laws</U>&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving
the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary,
threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(pp)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Private Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2,
no registration under the Securities Act is required for the offer and sale of the Common Warrants or the Common Warrant Shares by the
Company to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(qq)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No General Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the
Common Warrant or Common Warrant Shares by any form of general solicitation or general advertising. The Company has offered the Common
Warrants and Common Warrant Shares for sale only to the Purchasers and certain other &ldquo;accredited investors&rdquo; within the meaning
of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(rr)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Disqualification Events</U>. With respect to the Common Warrant and Common Warrant Shares to be offered and sold hereunder
in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive
officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s
outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under
the Securities Act) connected with the Company in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo;)
is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a
&ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has
exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied,
to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures
provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ss)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Other Covered Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered
Person) that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale
of any Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(tt)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any
Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected
to become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents
and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which
case they shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which
it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will
constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i)
as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has no direct
or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or
otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the
ordinary course of its business. Such Purchaser understands that the Common Warrants and the Common Warrant Shares are &ldquo;restricted
securities&rdquo; and have not been registered under the Securities Act or any applicable state securities law and is acquiring such Securities
as principal for his, her or its own account and not with a view to or for distributing or reselling such Securities or any part thereof
in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities
in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings
with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable
state securities law (this representation and warranty not limiting such Purchaser&rsquo;s right to sell such Securities pursuant to a
registration statement or otherwise in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on
each date on which it exercises any Warrants, it will be an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3),
(a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an
investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment. Such Purchaser acknowledges and agrees that neither the
Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the
Securities nor is such information or advice necessary or desired. Neither the Placement Agent nor any Affiliate has made or makes
any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public
information with respect to the Company which such Purchaser agrees need not be provided to it. In connection with the issuance
of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary
to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser
has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed
any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that
such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth
the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the
foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to
the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.
Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers,
directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>General Solicitation</U>. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice
or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or
radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on
the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or
similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE IV.</B><BR>
OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1   <U>Removal
of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The Common Warrants and Common Warrant Shares may only be disposed of in compliance with state and federal securities laws. In
connection with any transfer of Common Warrants or Common Warrant Shares other than pursuant to an effective registration statement or
Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company
may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer
does not require registration of such transferred Common Warrant under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT> The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Common Warrants
or Common Warrant Shares in the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED
INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant
a security interest in some or all of the Common Warrants or Common Warrant Shares to a financial institution that is an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser
may transfer pledged or secured Common Warrants or Common Warrant Shares to the pledgees or secured parties. Such a pledge or transfer
would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be
required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the
Company will execute and deliver such reasonable documentation as a pledgee or secured party of Common Warrants and Common Warrant Shares
may reasonably request in connection with a pledge or transfer of the Common Warrants or Common Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Certificates evidencing the Common Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b)
hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, or (ii) following
any sale of such Common Warrant Shares pursuant to Rule 144 (assuming cashless exercise of the Common Warrants), or (iii) if such Common
Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants), or (iv) if such legend is not
required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff
of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser promptly if required
by the Transfer Agent to effect the removal of the legend hereunder, or if requested by a Purchaser, respectively. If all or any portion
of a Common Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Common Warrant
Shares, or if such Common Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the Common Warrants) or if such legend
is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued
by the staff of the Commission) then such Common Warrant Shares shall be issued free of all legends. The Company agrees that following
such time as such legend is no longer required under this Section 4.1(c), the Company will, no later than the earlier of (i) one (1) Trading
Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser
to the Company or the Transfer Agent of a certificate representing Common Warrant Shares, as applicable, issued with a restrictive legend
(such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing
such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions
to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Common Warrant Shares subject to legend removal
hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with
the Depository Trust Company System as directed by such Purchaser. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means
the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the
Common Stock as in effect on the date of delivery of a certificate representing Common Warrant Shares issued with a restrictive legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>In addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Common Warrant Shares (based on the VWAP of the Common Stock on the date such Securities
are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day
(increasing to $20 per Trading Day three (3) Trading Days after the Legend Removal Date) for each Trading Day after the Legend Removal
Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered)
to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such Purchaser that
is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares
of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock,
that such Purchaser anticipated receiving from the Company without any restrictive legend, then an amount equal to the excess of such
Purchaser&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common
Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<B STYLE="font-style: normal; font-weight: normal"><U>Buy-In Price</U></B>&rdquo;)
over the product of (A) such number of Common Warrant Shares that the Company was required to deliver to such Purchaser by the Legend
Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the
date of the delivery by such Purchaser to the Company of the applicable Warrant Shares (as the case may be) and ending on the date of
such delivery and payment under this Section 4.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The Shares shall be issued free of legends. If all or any portion of a Pre-Funded Warrant is exercised at a time when there is
an effective registration statement to cover the issuance or resale of the Pre-Funded Warrant Shares or if the Pre-Funded Warrant is exercised
via cashless exercise, the Pre-Funded Warrant Shares issued pursuant to any such exercise shall be issued free of all legends. If at any
time following the date hereof the Registration Statement (or any subsequent registration statement registering the sale or resale of
the Pre-Funded Warrant Shares) is not effective or is not otherwise available for the sale or resale of the Pre-Funded Warrant Shares,
the Company shall immediately notify the holders of the Pre-Funded Warrants in writing that such registration statement is not then effective
and thereafter shall promptly notify such holders when the registration statement is effective again and available for the sale or resale
of the Pre-Funded Warrant Shares (it being understood and agreed that the foregoing shall not limit the ability of the Company to issue,
or any Purchaser to sell, any of the Pre-Funded Warrant Shares in compliance with applicable federal and state securities laws). The Company
shall use best efforts to keep a registration statement (including the Registration Statement) registering the issuance or resale of the
Pre-Funded Warrant Shares effective during the term of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Furnishing of Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to
timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all
of the Common Warrant Shares (assuming cashless exercise) may be sold without the requirement for the Company to be in compliance with
Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy
the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes
an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public Information
Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash,
as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Common Warrant
Shares, an amount in cash equal to one percent (1.0%) of the aggregate Exercise Price of such Purchaser&rsquo;s Common Warrants on the
day of a Public Information Failure and on every thirtieth (30<SUP>th</SUP>) day (pro rated for periods totaling less than thirty days)
thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such public information is
no longer required for the Purchasers to transfer the Common Warrant Shares pursuant to Rule 144. The payments to which a
Purchaser shall be entitled pursuant to this Section 4.2(b) are referred to herein as &ldquo;<U>Public Information Failure Payments</U>.&rdquo;&nbsp;
Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information
Failure Payments are incurred and (ii) the third (3<SUP>rd</SUP>) Business Day after the event or failure giving rise to the Public Information
Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public
Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing
herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public Information Failure, and such Purchaser shall
have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any
security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner
that would require the registration under the Securities Act of the sale of the Common Warrants or Common Warrant Shares or that would
be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would
require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing
of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Securities Laws Disclosure; Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the
material terms of the transactions contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents
as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release,
the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of
the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents,
including, without limitation, the Placement Agent, in connection with the transactions contemplated by the Transaction Documents. In
addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar
obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers,
directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers
or any of their Affiliates on the other hand, shall terminate and be no further force or effect. The Company understands and confirms
that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and
each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is
required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission
and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other
Person, that any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Non-Public Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, which shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other
Person acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company
reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented in writing
to the receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To
the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates
delivers any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and
agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, employees, Affiliates or agents, including, without limitation, the Placement Agent, or a duty to the Company, any
of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the
Placement Agent, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject
to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Use of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes
and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables
in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock
Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Indemnification of Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a &ldquo;Purchaser Party&rdquo;) harmless from any and all
losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any
Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the
Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the
defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i)
the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period
of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to
any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations made by such Purchaser Party in this
Agreement. The indemnification required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course
of the investigation or defense, as and when bills are received or are incurred; provided, that if any Purchaser Party is finally judicially
determined not to be entitled to indemnification or payment under this Section 4.8, such Purchaser Party shall promptly reimburse the
Company for any payments that are advanced under this sentence. The indemnity agreements contained herein shall be in addition to any
cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to
pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Reservation of Common Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and
keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the
Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Listing of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation
of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply
to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and
Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other
Trading Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary
to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company
will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply
in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The
Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another
established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other
established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Subsequent Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>From the date hereof until thirty (30) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter
into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents, other
than the entry into and announcement of an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent, provided that
no shares of Common Stock may be issued thereunder until after the restrictive period set forth in this Section 4.11(a) or (ii) file any
registration statement or any amendment or supplement thereto, other than (A) the Prospectus Supplement, (B) the filing of a registration
statement on Form S-8 in connection with any employee benefit plan, (C) as contemplated pursuant to Section 4.16 or (D) the filing of
prospectus supplements and any amendments thereto pursuant to an &ldquo;at the market&rdquo; offering with the Placement Agent as sales
agent, provided that no shares of Common Stock may be issued thereunder until after the restrictive period set forth in this Section 4.11(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>From the date hereof until one (1) year after the Closing Date, the Company shall be prohibited from effecting or entering into
an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the
Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right
to receive additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is
based upon and/or varies with the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance
of such debt or equity securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future
date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement,
including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities
at a future determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether
such agreement is subsequently canceled provided, however, that, (y) the entry into an &ldquo;at the market&rdquo; offering with the Placement
Agent as sales agent shall not be deemed a Variable Rate Transaction, provided that no shares of Common Stock may be issued thereunder
until after the restrictive period set forth in Section 4.11(a) and (z) after the restrictive period set forth in Section 4.11(a), the
issuance of shares of Common Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent shall not be deemed
a Variable Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance,
which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Notwithstanding the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate
Transaction shall be an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also
offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right granted to each
Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class
and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting
of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Certain Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants
that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such
time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.4. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4,
such Purchaser will maintain the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal
and other representatives). Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary,
the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will
not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.4 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, including,
without limitation, the Placement Agent, after the issuance of the initial press release as described in Section 4.4. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect
to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Exercise Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required
of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be required
of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to
exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms,
conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Form D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Common Warrant and Common Warrant
Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such
action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Common Warrant and
Common Warrant Shares for, sale to the Purchasers at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states
of the United States, and shall provide evidence of such actions promptly upon request of any Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Registration Statement</U>. As soon as practicable (and in any event within 15 calendar days of the date of this Agreement),
the Company shall file a registration statement on Form S-3 (or other appropriate form if the Company is not then S-3 eligible) providing
for the resale by the Purchasers of the Common Warrant Shares issued and issuable upon exercise of the Common Warrants. The Company
shall use commercially reasonable efforts to cause such registration statement to become effective within 75 calendar days following the
date of this Agreement (or within 90 calendar days following the date of this Agreement in case of &ldquo;full review&rdquo; of such registration
statement by the Commission) and to keep such registration statement effective at all times until no Purchaser owns any Common Warrants
or Common Warrant Shares issuable upon exercise thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>ARTICLE V.</B><BR>
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Termination</U>. This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder
only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other
parties, if the Closing has not been consummated on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>,
<U>however</U>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Fees and Expenses</U>. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise
notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the
Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus
Supplement, contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior
agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such
documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication
is delivered via email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New
York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to
be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written
instrument signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares
and Pre-Funded Warrants based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser)
or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment,
modification or waiver disproportionately and adversely impacts a Purchaser (or multiple Purchasers), the consent of such disproportionately
impacted Purchaser (or at least 50.1% in interest of such multiple Purchasers) shall also be required. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any
subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to
exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment or waiver that disproportionately,
materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the
other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with
this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred
Securities, by the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Third-Party Beneficiaries</U>. The Placement Agent shall be the third party beneficiary of the representations, warranties,
and covenants of the Company in this Agreement and the representations, warranties, and covenants of the Purchasers in this Agreement.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section
5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or
with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents),
and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for
its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such
Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Survival</U>. The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Execution</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction
to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by
such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission
of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and
the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Replacement of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed,
the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also
pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Remedies</U>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties
agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in
the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the
defense that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement
or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged
by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law
(including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent
of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force
and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Independent Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction
Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the
performance or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in
any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any
way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through EGS. EGS does not represent any of the Purchasers and only represents the Placement Agent. The Company
has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because
it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in
this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and
the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Liquidated Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the
Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and
other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Saturdays, Sundays, Holidays, etc.</U>&#9;If the last or appointed day for the taking of any action or the expiration of any
right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next
succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to
revise the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved
against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition,
each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><B><U>WAIVER OF JURY TRIAL</U>. <U>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER
PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY,
IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><B>Silo Pharma, Inc.</B></TD>
    <TD>&nbsp;</TD>
    <TD><U>Address for Notice:</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>677 N. Washington Blvd</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%"> Eric Weisblum&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%">Sarasota, Fl, 34236</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD> CEO</TD>
    <TD>&nbsp;</TD>
    <TD>E-Mail: eric@silopharma.com</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">With a copy to (which shall not constitute notice):</TD>
    <TD>&nbsp;</TD>
    <TD></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">Sheppard Mullin Richter &amp; Hampton LLP</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">30 Rockefeller Plaza</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">New York, NY 10112</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">Attn: Richard Friedman, Esq. (rafriedman@sheppardmullin.com)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">SILO</FONT>
SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrant Shares: __________________ Beneficial Ownership
Blocker  &#9744; 4.99% or &#9744; 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Common Warrant Shares: __________________ Beneficial Ownership Blocker
<FONT STYLE="font-family: Wingdings"></FONT> &#9744; 4.99% or &#9744; 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings"></FONT>
&#9744; Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the
above-signed to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the
obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall
be disregarded, (ii) the Closing shall occur on the first (1st) Trading Day following the date of this Agreement (or the second
(2nd) Trading Day following the date of this Agreement if this Agreement is signed on a day that is not a Trading Day or after 4:00
p.m. (New York City time) and before midnight (New York City time) on a Trading Day) and (iii) any condition to Closing contemplated
by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed of
any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall
instead be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument,
certificate or the like or purchase price (as applicable) to such other party on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ea025946401ex99-1_silo.htm
<DESCRIPTION>PRESS RELEASE OF SILO PHARMA, INC. DATED SEPTEMBER 30, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt">Silo
Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SARASOTA, FL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.
(Nasdaq: SILO) (&ldquo;Silo&rdquo; or the &ldquo;Company&rdquo;), a developmental stage biopharmaceutical company focused on developing
novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered
into definitive agreements for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share in a
registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered
warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that will be immediately exercisable
upon issuance and will expire five years from the effective date of a registration statement registering for resale the shares of common
stock underlying the warrants. The closing of the offering is expected to occur on or about October 1, 2025, subject to the satisfaction
of customary closing conditions.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">H.C. Wainwright &amp; Co. is acting as the exclusive placement agent
for the offering.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The gross proceeds to the Company from the offering are expected to
be approximately&nbsp;$2.5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company
intends to use the net proceeds from the offering for working capital and general corporate purposes.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The common stock (but not the unregistered warrants
and the shares of common stock underlying the unregistered warrants) described above are being offered by the Company pursuant to a &ldquo;shelf&rdquo;
registration statement on Form S-3 (File No. 333-276658) that was declared effective by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;)
on January 30, 2024. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement,
forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered
direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained,
when available, on the SEC&rsquo;s website at&nbsp;http://www.sec.gov&nbsp;or by contacting H.C. Wainwright &amp; Co., LLC at 430 Park
Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at&nbsp;<U STYLE="text-decoration: none">placements@hcwco.com.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The unregistered warrants described above are being offered in a private
placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and/or Regulation D promulgated
thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities
Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be offered
or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements
of the Securities Act and such applicable state securities laws.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release does not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Silo Pharma</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Silo Pharma is a diversified developmental-stage
biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced
psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company&rsquo;s portfolio includes innovative programs
such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer&rsquo;s disease and multiple
sclerosis. Silo&rsquo;s research is conducted in collaboration with leading universities and laboratories.&nbsp;silopharma.com</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This news release contains &ldquo;forward-looking statements&rdquo;
within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995. These statements
are identified using words &ldquo;could&rdquo;, &ldquo;believe&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;intend&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;expect&rdquo;, &ldquo;may&rdquo;, &ldquo;continue&rdquo;, &ldquo;predict&rdquo;, &ldquo;potential&rdquo;, and similar expressions
that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors
that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including
statements pertaining to the completion of the offering, the satisfaction of customary closing conditions related to the offering, the
intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties
in developing the Company&rsquo;s technology platforms, retaining and expanding the Company&rsquo;s customer base, fluctuations in consumer
spending on the Company&rsquo;s products and other factors. Accordingly, although the Company believes that the expectations reflected
in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company
disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release,
whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence
of unanticipated events except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">800-705-0120<BR>
<U STYLE="text-decoration: none">investors@silopharma.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>ea025946401ex99-2_silo.htm
<DESCRIPTION>PRESS RELEASE OF SILO PHARMA, INC. DATED OCTOBER 1, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.2</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Silo Pharma Announces Closing of $2.5
Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE)
-- Silo Pharma, Inc. (Nasdaq: SILO) (&ldquo;Silo&rdquo; or the &ldquo;Company&rdquo;), a developmental stage biopharmaceutical company
focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced
the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale
of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a concurrent private placement, the Company issued unregistered
warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share that are immediately exercisable
upon issuance and will expire five years from the effective date of a registration statement registering for resale the shares of common
stock underlying the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">H.C. Wainwright &amp; Co. acted as the
exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The gross proceeds to the Company from
the offering were approximately&nbsp;$2.5 million before deducting placement agent fees and other offering expenses payable by the Company.
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The common stock (but not the unregistered
warrants and the shares of common stock underlying the unregistered warrants) described above were offered by the Company pursuant to
a &ldquo;shelf&rdquo; registration statement on Form S-3 (File No. 333-276658) that was declared effective by the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) on January 30, 2024. The offering of the shares of common stock was made only by means of a prospectus,
including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying
prospectus relating to the registered direct offering was filed with the SEC. Electronic copies of the final prospectus supplement and
accompanying prospectus may be obtained on the SEC&rsquo;s website at&nbsp;http://www.sec.gov&nbsp;or
by contacting H.C. Wainwright &amp; Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail
at&nbsp;placements@hcwco.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The unregistered warrants described
above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not
been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying
shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable
exemption from the registration requirements of the Securities Act and such applicable state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">This press release does not constitute
an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any
such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About Silo Pharma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Silo Pharma is a diversified developmental-stage
biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced
psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company&rsquo;s portfolio includes innovative programs
such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer&rsquo;s disease and multiple
sclerosis. Silo&rsquo;s research is conducted in collaboration with leading universities and laboratories. silopharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">This news release contains &ldquo;forward-looking
statements&rdquo; within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995.
These statements are identified using words &ldquo;could&rdquo;, &ldquo;believe&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;intend&rdquo;,
&ldquo;estimate&rdquo;, &ldquo;expect&rdquo;, &ldquo;may&rdquo;, &ldquo;continue&rdquo;, &ldquo;predict&rdquo;, &ldquo;potential&rdquo;,
and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties,
and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such
statements, including statements pertaining to the intended use of proceeds from the offering, changes to anticipated sources of revenues,
future economic and competitive conditions, difficulties in developing the Company&rsquo;s technology platforms, retaining and expanding
the Company&rsquo;s customer base, fluctuations in consumer spending on the Company&rsquo;s products and other factors. Accordingly,
although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance
that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to
the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise,
after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">800-705-0120<BR>
investors@silopharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  G 0D# 2(  A$! Q$!_\0
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M$?Q+XFT_P5\.= U(.^D7?B^<?;[BZU>6)@(M&T32-+U&]N)20G]JVUC;MS,
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M8HW^GZ7H\\8.Y3QO(P,AG!!KU[X/?MF_LO?'^^_L;X*_'_X>>/\ Q (GO?\
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ME\)-,\+>'],N]8L-%TV;7()-%8I=:[/,T$$$9TZ55Q"%* E/E:OP._X)C_\
M!&?]HGX:^-?CAH/[7_@K0;7X0?&#X%^(/AKJ;>&?'>B^(;V+4;OQ#I%^KE-.
M-PZZHDFG+-!<*ODQRQQR8$J*1\9D7'.49CP/Q?1XDS7!8W&+B6G.ADD*=!UG
M3]O"K)4I1I*I&E""<$N>-XNZYKW/K>(N!\XR_BCA.EP;@\7@,!+AYJM*56O:
M=7V5IN?-5:<Y3;=WJF];):?SR_  >#_BI\<[WQK^T;X'^.'[1NEW<6M^(O'&
MD_"S4I9_B5XTUO49Y+J*\U#7;R"XO-,\*+J%T;B1HTAAAN;BWTZ)XUV*OKG[
M0GP7TN_\>^%/''[&'[*7[8'P;T?3K6RNM0B^(.F:SXEUG1/&.G:F'@U?PMXD
MLM.-S92+'L61Y)3O8$C"':/U./\ P1[_ ."G'[#?[0.H_%?]BGQ#HOC32=/&
MI6'A;Q3#XO\ #VB:S=>#=0=)9=#\9>%/%,MI'?K;R102:C&&GTMI(8[FUNXI
M@K+[!:_L=_\ !?S]IOXGZ#XF^+'Q=N/@-H=BUKITNMZ#\2M&T_3M/T.=P;F\
ML/!/@S4[J#5=0)._S;])9/N@/]VOT'&<691&K3SW+LZX0CP_##PIO(*N9XZ*
M<U2@I1GP[# NC.=U95/K/-S<UTDV?"X?A#B5T*F6XO)>*_[:EB)35LMPLL4X
MN<K2CG3QG)&#3Y^39I)MJ5D?F)_P45^*OQC^.'[,/[!/BG]H2Q\16/QBTO1?
MC%X/\42^+]+N-*UG4O\ A&_$SZ;8:W?Z?J-M;?)KFDBU2TGD7/F%I(V#$D_3
M'_!.?_@B3X7_ &X/V5[7X[^*OC[K?@G5]9U?QCX8\(^%/#/AG2-5T+P[/X6U
MF\T>>7Q+/?2?;)([G4;4ZL\>F/%LM)C@E25KM?\ @X#^&-U\&=)_8J^&&I^/
M_&7Q5U'PW\/_ !U;ZAXZ\=7L6I^*O$=Z^K0.[ZJJHL;()<^0=QDBC"KG<N:^
M6OV/OV9O^"N5[^RS:^.OV+/$_B*3X$_%R7QAIGB;PIX4^(/AS2+R*ZTK5+WP
MYJ%Q#I.N&:XTJYNIH9FNKG1I;:ZG;<TSLYR50JT,=X5Y+C,DSW+.#JU7BF:=
M3%TJ-IJ6(JU'&$JM&51PY'.<*<GR<J5-VA[QI.A7P/B!GF SS(,PXP64X;#2
ME1PU6NO9MY+M-4JR@YIM1FTG[Z<KN5CR?_@EY\9?B;^RM_P4.^'G@_PCXFD&
MD^+OC+!\)?BCHND.'T'QYX<U'Q!J.BQW-O"K&W&JZ;JD$.KFX=6NH+4& 2B,
M$5\>^!OA)_PNG]JZP^$5AJ%CX4O_ (D_'[Q=X.MO&#VT-S'X<74/'&MH+^>9
MGAD1K:VWV%RX97>:92Y+ 8_I$_X)3_\ !$[XT_#7X^^%_P!HG]L/2]-\(67P
MVOXO%'PV\!Z7XELO$>NZEX[U.;_2-<\8W>C17>F6B6\URKRZ2UV;F2_9)(Y8
MH?,6OYM_!GPN\9_&C]IZ3X6^ +P:7XZ\=_&SQKHW@ZYU&[FL(=,US4O&/B2Z
M@N'OK"2.XMF+61E!25)8VY5@R[J]7)<?P[G'%_%]3A_,\#B,3E' LW5SY4,/
M]56)@I<]7E]DH.2?.^90ND[1E9,XLYRW/,FX6R26:83%T<'F_$T52X?G6K_6
MO92E&48)^U=1+D<8<O-9M:QN?J5_P5&_X([^$O\ @GW\*O GQ3\&?&+4/B)I
MOBCQ5!X'\3>$O&GA_2-'OY]6:PN'_P"$D\.SZ2'-W;0R++<,DJLS17$)EWGF
MO5/A+^U.?C=_P1\\;_";]I+]I/QS\'?#OP4^-6@?#.Q\4^%[!M?^(GQW\#/X
M<MO$NB?"Z&QEE$TMOI#Z@EGJEQYY:71])MS<$+,5;AOC5_P38_X+;_M(^(?"
MG@_XW:=XB^(6F?#^"#1_"VJ>*_B=X3/@C2[(A;236[6;3GMHI%%O%&LMP\>H
MZZL*B.5VD# ?I/\ &K_@A?XBE_X)Z_"GX'_!KQ1X7U+]H7X6^.]6^+_BO^T=
M4?3O#7Q$\8^/= MM"\3Z?9:U/;,]K86&D6]OI?A.75+6!+,0222M&SIGX3'\
M2<-X?)N%\LXAXFRW-,^EQ31K+.Z%/"JC2H2G.<:<W["TH^S<:<N:*;=Y0BI4
M8S?UN"R;B.MF&>YIP[PWCLCR.GPU4C+)L34Q+K3J*"A*I!NIS<TFI5$XM737
M,[2<3\,/V;]"_86N8O$T-S^Q[^VW^UY<3:C/'HVL>#-=T7P5HWA32]@ABT5;
M;PQ;>5>:M%.K:A/<WDKWUHDJ1>4WE$/XW^S5J&H?![_@H%\%]1\!67B3X<2Z
M!\?] \/Z3H/B06^F>.]"T/Q!KMM9KX5\9W-BQMI8+32[R6SNK</+_:LY%W=1
M13R,J_KS^RO^Q/\ \%V?V=?"/B+X)_"#2M!^#'@3QOJVHWNO>(-8\>?#>Y@\
M,:E<0"PO_%.E7UG>ZCKCW&JVX@M[=]-M[FXM)8H[R.&.8 #R'P+_ ,$2/^"B
M7PQ_::^'WCB^\&>&/BWX<\%?%OPCXVOOB+9_%GPQ WB#2]/UVUU+7M:M]'\4
MWMAXCOKR%WO'O9;RT>XOIH3+']Y0/L*W%W#\'Q9AL?GO#O)F?#=:GAO;\78W
M/=8TYQA*.'Q& P]#"U&TDHT)6A=0E4M!'SE'(<^C'AROALBSWGRWB&C4KM<+
MTUSJ<H3E&52.(]I7@E+1U=^D7S._Q-_P59L9Y_\ @IW^UE#8P8OY/C391Z=*
M!"#'<1Z9H4&DR.6&2S7]P@C9R2'5"#\H-?I=??L.?M(_\$I?V2/VH?VK-:^,
M?AGQ'XS^/WP7^'_PBTZ3PE9>*[/Q1X)U3Q_XG@U'4-9U37-7D>VO(;/3+N;3
M)+BR;S(;LF2"5-L=;W[<G_!'?]N[XT_MV_&7XX_#SP/X,U+P%X_^*FD>--!U
M&_\ B5X2T_49O#<3^'GU*631;B]74C<VTFFSM91"$D''EG+<_P!/'[3/[,FC
M_M5?LG_$']F[QB\^F6GBSP1I?AZUU> I--HOB[2M,LI[#54Y"M9Z1K-I HV_
MNKH23N <;J_/,X\1,FR_A_PMRS#YG@LTPL*]%\3TXT<+5E"C3IY9>E.?LI2D
MHJ#7,I2;E33O+F:E]UD_ 6;YIFWB+F-3 XK*L52IUY\-J=2M24ZLY8B<6H*H
MHZN22C9*'-RM*R:_BN_X),?\$L?#'_!1&^^,VI>/_B?JOP\\)_"R;1M,N=,\
M/V^GZUXO\0:]XBLI=6L[VY776>6?1+""&6\FOYA*UWJTYMG9OF ^%/VR/V=8
MOV4_VJ?B=\ +/Q<WC;3_ (7^++*PT+Q'<*D,T=C<P6%ZD%U%$?*M;E;>\475
MM;X@CE,BQ#R]N?U;^'G_  28_P""S?[*?Q7U#7?V<;C3/#VJZE;2^&X/B=X!
M^*G@'2]-US0MA#'6O#/B>X:=Q X,S/<:+=36\S.;)E4*3RGQ!_X(6?\ !437
MO%NI^*M<T/P'\3->U_48?%/BCQ=>_%GPTUYJ.NW4L,NJ+J$VNWECJ,\FYW\P
MQ6SVJ@*EJJPB%!^EX7C'A["<2YIG&+X[RO$\(X["QAP[P[0C0AB\KQ*BHRG5
M=.E3ERQE=*3J2<N:SA%03E^?YAPQQ!BN'>&\MP?!./PW$V#QLYY]GE1UY8>%
M#VTI*;C.<H>]']XE*#23T<N9I?=O_!5I=OBW]E9/E8+^RS\.EZ JQ71[4 X.
M01D CZ#T%?,_@+^T/V5?B5^QE^T#;75Y%H7B[P]X2^),ETH:1+BUC\7ZUX;\
M?60)/,,%M#96TD1_=E[M-RDL!7ZT?M\?\$\?VH?C[J_P'UCX:>&O"UY:^ _@
M#X2\#>*?[6\:Z/HWV/Q%HVF6-O<6]K)>SQ13P)=0RQQW4;-'/'B6,F.3G4^-
MW_!-KXR?$+]B#]EGX=:7HGAZT^/OP*BUFPU+2I/$FEP^'[_PUXMU*^NM6AC\
M1))/IC):W$MC?)&T_E+-$UP(T=(VK^*<7)3Q>*G%WC/%8J<7WC+$XF49?]O1
ME&2\F?W+E\7'"X6,M7'"X6$M-'*.$PL)/M9RA+IY'YY?$K5(?V_?VY?C3XUA
M.H:G\-/#G@3QEXCTZ13);&T^'OPP\'W1\-63%'PD^M>)?MEV"#N>.\C#,V :
MY?\ X)0EI?VSO"C2;?-_X4_\:Q(R@!=Q^'FL;PA'1-Y) &!W'-?JI^PA_P $
M\?C%\"?AE^U+>?$;2-!M/B3\4/A[=?#GX>V6F>)M'U:SCT^^TN>:[CO-7M+E
M]-LRVJ)ID*SRR1'R3('P&*GR7_@GO_P3<_:C^ /[47@WXE_%?PGX<T?X?V7A
M?X@^'-5N-%\;^'=>U")?$G@F^T:Q1;?3;JXES)?2>6& (#X<ACUEVLU9;67W
M>G]/\.@_-'_@G'!:K^W;^S].\2(9/B!&D,C-&SRRFPU!9"#RQ\S;\PZD  \#
M%?L/_P %ZKS3G^%_P#T6=K:74;GXE:W>P()(C?)I=MX7O+6:ZBB/,@35KBPC
M4X(&Y0.<"OC3XL?\$F/VO?AA\9+[Q1^SM;:=XM\/:?XBE\2^!/%6F>+-%\'^
M(O#UQ+=RW5N+NWO+D26DVF0S+;&X#>3>&-V,!60QCI?C)_P3?_X*1?'W0M%^
M(WQA\8Z)\1/BGIM_!H&C>#=3\7>';2U\/^!9]-N;BYU>77T&F^&IKFYU2.TM
MYAI<<FIL;AWD8R0 J:7OI:VUO^ !X)XMVC_@D)\) A)0_M=^)",J$+8\%ZH5
M9D4!58$!L #8WW<8%1_#,*?^"3O[3' (_P"&A_A5V!'_ !^62_R 7Z #H!7W
M'XA_X)X_M1ZA^P-X _9OLO"WAR7XHZ)^T%KGQ&U?3G\:Z,FC6/AF_P##=YI]
MM<Q:@[[99#,RK% ?G#F7?G=@3^"_^"=/[5>B?L%_&CX :EX7\+2?$SQW\7_
M7C+1+=/&F@RZ3=Z/X;N]/N+Y;S4HY4ATR:.*SF58C&7<L0P8LU&FNV_EM_28
M'P_^SNBR?\$O_P!O19%617\:_ X.KJ'5A_PD<"X96!##:-N"",<=*ROV#8HH
MOV=_^"CWEQI'M_9LD(,:A""MS=;2"H!!7 VD<C QC K[S^#_ /P3E_:F\'?L
M/?M2? O6O"OAN'Q]\5O$?PUU/P7;0^/-"O-/N;3PCK$E]>'4M72>.&R=$VB/
MS$8R!%!W<XS_ -E;_@G;^U-\)/A'^V'X1\<>&/"EGKWQB^#5MX(\$PV'C?2-
M4AU+77O+NZ:"]OHV6&S1H#^\<Q, /XBHHTUVW\O)=@/S/_X)Z?LI2_M;_&'Q
M%\-[GQGJ/@3P?I_@V;Q%X[_L%VBUOQ+I46I:?;0Z+:/$R6[R2W=W9ZF(K@.#
M#ITI=#AJA_;U_9.TK]B_XZ:9X'\(^)];\0Z)J?@ZU^(GAK4[E;?2O$&@++J&
MK6JZ3'<6P4MJCW.C&^^T6Z1.RAF0*IQ7[(_\$L?V#_VB/V4_C+X\\9?&3PSX
M;TCP]XB^'DWAG2[S0/&.C^([DZQ)XA\.:@?,AL;F652MO97-NMRT$<K13/&0
MJRNAK_\ !4/]@K]I/]JKX[^$_'OP>\+>&M2T/0?AQI?AZ\FUKQ=IOAJ3[=::
MOXDO&,4D[.Y(BU18PQ562/*$[05HZ]+>B_R[@?J/^Q'XL\1>./V4/@+XF\5Z
MQ)K>NZQX!T>:_P!<GF,LVHKI;)9K<W<S',MS=E \\K?-(S%FS7U%B]_N2?D?
M\:^:_P!C[X9>)_A#^S5\%_A9X^M+33_%?@SPC_9&LV6GWZ:G:07-O?&[>-=0
MAQ%=Q*QV)=*%BN$ =,*P ^G/,U'_ )Y6_P#W\'^-8_YO\V!;6VMD&%@A4 !0
M!&@  (8 #&  0"!V(!'-/:&%\[XHWSP=T:MD>AR#113N[WN[][N_W[_B2H02
MLHQ2[*,4ON22_ C>SM),[[:!\H\9W11M^[E_UJ<J?DD_Y:+T?^(&E6VMDQM@
MA7&0-L:#&=Q/0>K-_P!]'U-%%1R0M;DA:][<D;7[VY;7\]_,J[M:^E[VZ7[V
MVOYVOYE=K*)FW-#$S''S&*,GY<[>3S\N3M],\8J065LOW8(1\K)Q"@^1SEUZ
M?=8\LO0GD@T441A"+E*,8QE-\TY1C&,IR_FFTDY2\Y.3\Q.,6XR<8N4(\L&T
MFX1_EB[7C'RBXKR)1;6X+'R(<MY>X^6A+>5S$&)&2(CS&#]P_=Q2F"'&WRHL
M8P!Y:8 !R!C&, \XZ9HHJKM)V;V?5_YCMK?KWZ_?O^)^77[=O_!+SX"_\%"-
M1\!ZM\;_ !%\4='NOAQ'J^G^'1\-?$6B^'MZ:G<)=,UT=9\/>($<XC (**N<
M9QCGW/\ 9'_9F^''[&WPAT+]GCX5ZOXIU;PCX6O/$5_I;>,-0M=6\223^)=6
MNM>OA-?V6D:'I3;-2NIC$6@4")47@ 445Z$LRQT\F^KSQ-65"G^\A1E.3I0J
M.<H\\:3;A&=K^]&*;N[L^8I9#E<,]GB(8:,:]6*=:K%M5*ME*WM9I*51))12
MG*5H^ZK+0^O1 AB6142.3"[RJ*&9U0*0Y4<X"[3ABN!M!*8K\+?A[_P0:_8X
M^#7QGTC]HCPOXO\ C[#XH\'>.KGXF:?%JGCCPW=>%?[<FO+Z]GCETRU\$KJ[
MVB7.H3B&+[0S1PML#L2S$HK/*LPQF#A5^JXBKA_;KV5?V,Y4O;4VE>%54I4U
M5@[N\*BG!IZQ-LVR#*LWQ-!9AA88A49\])3=_933@E.G=/DG9+WH<LM%J?NY
M:QPS0HS1QR+-#$Q)0$2*T:,N=RJ67YB0&53SDHIRHE^P6)<R&SM?,(<;_L\6
M_$C*T@W;,_.RJS\_,RAFR0#117%.,9M<T8RY9\\>9*7+.[]^-T^62Z2C:2_F
M/?C",%RQ22Y%3>FK@DHJ,GO)6234KI]42FWMV#!H(2'!#@Q(0X8@L&!7Y@Q
M)!SD@$\BD%K;+&T2V\"Q-]Z-8HPC8SC*A0IQDXR.,T44G"$FW*$)-Q<6W&+;
MB]XMN+;B^L6[/JBEHK*Z5[V3:5UL[)I75E9VOHM1?L\&Q8_)BV+MVIY:;5V_
M=PN,#;U7C@\CF@6\"@A88EW+L;;&HR@S\I( )7D\'CD^IHHH4())*$$H[)1B
MDMMDHI+9;);+L@MJWU>[ZOU>[^;8H@@7.V&)<X) C0 E1M!( P<+A1GH !T
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L& ,8Y/YFBB@ \J++-Y<>YQAVV+EQZ,<98<#@Y'%+L3^ZO_?(_P *** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) )8# 2(  A$! Q$!_\0
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MXI_+:_7KK\C0@MUT.WM[:VC+VO";01N#>OOD_K4ZSR7=P85C>*- #(6X8YZ
M>E4K.]DUN% H^S20,/M",,LD@_A ].^?I[U<6.:TN6F9_-BD #G: RD=#QU%
M>15]JJK4K\M]=OGYVO;_ (8]6E[-TTXVO;3^MK_UN70   !@#M2T=:*[#(**
M** "BBB@ HHHH ***PDO]6U.:X.F+:0VT$K1![A68R,O!( (P,U<8.1$YJ-E
MU9NT5GVUSJ,EE<>?9HEY$"$4/F.4XR"#U /OTJK?WU_;Z19S2*D%U)<11RJN
M& #. 1^5-4VW8EU4E>S^XVJ***S-1-HW;L<],U7N?.F'D0,8\_?E'51[>_\
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M14%&S>COV\_G<ZBBBBOJSQPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
.**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>silo-20250929.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSaSLaaPtypR1WYkxs2tyHSmKPy4mdsPwFyFic/fmQYIE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:SILO="http://silopharma.com/20250929" elementFormDefault="qualified" targetNamespace="http://silopharma.com/20250929">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://silopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="silo-20250929_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="silo-20250929_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>silo-20250929_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>silo-20250929_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="silo-20250929.xsd#Cover" roleURI="http://silopharma.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://silopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 29,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Silo Pharma, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001514183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3046338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">677 N. Washington Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sarasota<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-9031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SILO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0259464-8k_silo.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://silopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0259464-8k_silo.htm">ea0259464-8k_silo.htm</File>
    <File>silo-20250929.xsd</File>
    <File>silo-20250929_lab.xml</File>
    <File>silo-20250929_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0259464-8k_silo.htm": {
   "nsprefix": "SILO",
   "nsuri": "http://silopharma.com/20250929",
   "dts": {
    "inline": {
     "local": [
      "ea0259464-8k_silo.htm"
     ]
    },
    "schema": {
     "local": [
      "silo-20250929.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "silo-20250929_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "silo-20250929_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://silopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0259464-8k_silo.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0259464-8k_silo.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://silopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001213900-25-094711-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-094711-xbrl.zip
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M3?)RZ#]*E!*]]"%IT8&/UO4Q6&$PQ6:Z!HV'G8,MI\%[?S5?0H,2>QS+./W
MZA,A"S(JL5W6':U*\UHYICZ)CH-0>:JE@ASYC_[\Z/JC!?ISYC*T]-AS+/J&
M,#YQ3X?#51'UJ5Z]U/Q*K_>Y\A)ZE-AP6HW;#ZQ/@'1>CV']H%_2JD:^O#'8
M?)QVR;'_Z->/KE^5=/WJ>MZ$N0]J6=\:L^'DT]$?I_PEM*QZCY8M8?BF=*W"
M\M4-_7&Z%HQ]U6K20K[T&NEL+!*6^25S(4-=)IVP4?8P@T0#6KVM?/'M-P^=
MXU%%V3RICXAN4L_[9=HSSEV*4D+Z\_' -C>PIOV+K/PD: MDRLK9%IF..$A
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M$,9W04PG!)2JRMV]R./0 <O<LW74::N%-187EO29\?7%%J#POF7,>1B?3(0
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M\7,ITD43FZ@,\)B@WU./9KD>1R<4LCYO#$;1?QS&S_?W8^RD"G^IHZ1UH+_
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M7?/Y#A PPS2%+"L4;2]6*?"4-70PI&+P@$_-5MYZ8&M .%&DG[+&S&ODX%<
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ME96$L]YB43JWP<O"(U]C8/^D][6Y+1N\@PB8$@N5:5<V4 F/!!?]R[;5\7!
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M1C,SJ$7'<V3EM\;/0*G.-(99)P!O1M$MU#J"ZCQ,^L?U=[J2$2D=[^8^.1K
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M-@MC6?),;Z$;\3;,AL"C+YSG1!)CDW2183$1L/QIV:=7&DA(L=U?8:A@G8M
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ME6(B=S16%F=3L2Z94+/Y5);&],^@!<?N/E#*P.)![G7-TE\4UT"#3^GZ/J)
M&B[:IQK5 '-H^F,A](/9#9:<P/^Z$;ZY<5LK/';=D&_HG[U/?P+7>08;N+T3
M)+M\EPYPVX #O'O)G1<"ZIK<_2#F0+I #?KO5O@!^&GN*,';1U%V,AB 1<7;
M$?G+%\M $1[&-RPF$"44D/>#B_1J:[@6*_)&YK/(7S6K#7-*#<YED/BX=/W;
MD^E7D"/O[F!=AH03'C[9>,R?:P7<+E:\+N6W 2JWG#K'L);@7%RV=$"8Z!P
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M2!,@ODJGE02H*!M@FJ!.A=XN.7WGO0WG-=DGLN8J8;RW%6.@=04,#Y@WB]#
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M4="-<UNKK@>W@'@%$&=>G<_F]"@Z<X'Y6L%8$B&<QB>0JMFX7SAOLYA/W-V
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M]_KP[3]>P3]^/?UM_]7_!U!+ P04    " #+@T%;3#9#9+1%  "W<@$ &0
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MP:@Q^G#_/(!1=WYZ^C0,AO#O=R-X["#8P.?^EL7_6A0OW<?_5M*'@[#?@Y>
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M[\%M;&G'6^:.%9U)W^1D&56@9LU! \!S%K.N96E'LVB)=_8LBN%RAEO@^K(
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MB@MX/YW)0;<RFM1$!3L:@/T4TZQ!72(&+@-N=LG M>_*3LY+\^8>J_H%4GC
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M_.D/SSGUC[+%E7L+&Q04Y<#:<3L)VHXV&PWP]Y%MA7J'J>1\C\28\D;,0N;
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MK$O8!(">;("!7#AC$\I%7/_M/<CD-4GNN9]=#<1='3K=S%DSLLEKN:E)!.5
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M]MWNSM/:U4SC"6P+'$_PM\#_6>.@:*EIC>=EM[,EEN3/O_3/&Q2#()F"09'
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M71&!'$)\>PH,EZ75=0Z<'<8!(3-<,$[GW( X:;AI]&M>(-%BQ 'MNMAP$4L
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M1F?+<G_GC:@':I?N(HL$6UT?":&3,V'?^BZ9XR$+M9S'4O,+4Q[YLN'>8"J
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MY1.=+M^6J$M':?H2I#A!_!/.;^S.;^K,SZUG5AB\:S"*BXJA4BH#VZ2INK>
M32RN4A*3F6>-+_W!U0Q"0I7"IDXS27'4I0*65$5(*MV]U>M\:,VFH8.K"A.5
ME83@Z : ;BL)KEXX$S^2.)";#FQM4&US*"HAFXIN8#>, O/!UD,</FOUK]9W
M'#<Q^8!ISQ0&R\;BX&0<GE26,3.E?4F3>+[6E#<7>3UWY).-.U*Y(Y]LW)'?
M%'VS._(RJN8%XK]#!+QD]"=4:A+^4UR-G.;@A$?/R:N!.>;QF(IP*4]<I8$,
M9.UH@<)ZVBPI-,_4:I0)@.<%IWV@UB%A=,=C$SE%D*2&+&<:\4"J AZAR%6I
M)1[$#_0JM&4&^\+UC+B;CCW"A@6*3Z^O,^V!1$B</T1JX7H3VWNPA*Y[;4RC
MFL:%)\,&F*^M$-7:$E:L Z#?H5#%,RD>; H<L#=1(IUN@2 ;<E0O/8.@$H9I
M-U9#:'"O:%"2K>*3T:6\:F+]U&M>N-JKE.3L=CPU-I&8;5,_/I4HHP'DA/!0
M.U&)HE=*-+_ 7@<YA=EA9L6U @D0\&3."'@<2</)LQ@K96#>SSJ+=F ?:RZ:
M3K*B1I)IJE(*=/4M75>K5 S)S$@*FJG> DV^)Q7+ESSHTB#PA5UJ!['MC?+\
M3FETQXU!KB5#/63[6UBR[17.W0J*[Z+B0RQFB)-D9JA19IBBIVJ\U)B)3 A?
MEH<U;6W$ J]R[9/1#DD5!+-+?258PJRA8-;2UXAWU ,$J"*!NO.@[YYL@1HA
M_@#!A>96AYRJ@8A$@8<@L2]4[5ET6F:86%>6'#R@(!6ZS;E>$1':1^1IH-1G
M[(;E:U &(^K+48L&NK7P%3.(M2-SB[TPU,V#H8KN+[B8N(ZOC'0B*)=FS N=
M<V$P&S3"Y^Y =S]F_?7%Q4!<3AKBBQW\**D&;O%=1,5_I<X44S#&=6W7?!.J
MD]2BA:5I69TX6["]0+ETE9&'6L8>M[3-O$X=U4V1SZ]5:JK;R,8.LJGDSY9,
M*2?%LMY>VXZ%<6-[)D*3HZD;,& ](G8'Q!^(7]('N#'Y$&6GZLD%0I<"75:-
M,2%WZA9?#QMB93D..Q!CXH+Y1/S7.4CO2421@[($MF:<"T5!L##<8PZ 2>R+
MAK"0L)9.K)Y1_8B:Y #KUJI7!CEMI/H;Q\RUZU'EB7KN3I=A76/>%5:$ Z92
M4"2L[M'$UU['&1:)LM+&T!Z[SHF4*CL5B_8)'8SB0T'QQM[>652XU6;]>@+#
M7-KL2#5^A8,F]H/\='G?'';[<DB$(<,R.$//>6S5%LX1P:J:W\KMIB9<Q5C5
M5?<#H(I?4ZW.-+YF.#F1]#+6O::VX0D:;OB&&<.4)%:,&+UNJ1/Q!$^]I!WA
MFLK6DD7,1))PR@$C'1AF1E.JTG<+%2(6M0!]:L-\O%"8UE_ACI9CCBPK:1&:
M_0S-AM)DXDR=J]X^)&.^EJS 6975&G2J[UM:'$C_8V8<7 %.(!"D(?G=>Q%!
M;>IZ*,Q.&P)QO5Y$)NO4K332"!!=3GPF7DE_T^1CTZ& (,/&.]I.I*"B(94B
MBB(?HPQ90J\;<WX]C^;3C4=3>32?;CR:WQ1],\;EOZS+;Q5E@\,KF0-A)Z2X
MR)3N0]X&'7M2Z?,@,A$N)>7H69\#<@/KL&J.C!F8N2G9T(1DKT.8-IBEI87-
M:D!""JMJ_7?T(<OOTGA\'9=&:_-5SY'XF%>J7A2JX[[K"F]CRERHW"7!.JB&
M%!R6=^+Z F.2]BX6*D^"N&3^@%:>EVRE,QJ(+/P8.P*D?DKIAAKVKP6ZDI'!
M7+!#9/!QALV:!6%ZBGDR\X*/=1Q'*8.ZI*Q&&I&J8)7AT%1@PA$F4U8HA:!>
MQMX2C6<6<TD-3&!C"[[0<55^D0*UW'%][_A7,,Q'-BY&]VU0B!BJ;%RR=PZM
MGKALP9_H6B9NU3F#=!57;U.6L%M;F,B4;1?<3;Q*, @6S8!-*G7>T<* ;UO+
M68>B5;)>6E*:(1M.7/,C&$?3Z#HN?>QU79W$M%FW&!)KE60UDM6L>:V;;XL^
M1E6!JF1D(CI:F$)LYP@:_'C):5?)W1(Z?EI)P"KEB.!24B%*W1<-SD0<X[,9
MQ=>)I4L0B9]$Q("7Z<5M6O)4=0HBSXTL:CRW4H(D&9EU<$-$+) T$7#IK7;B
M,:2\81[[-U:-3%VJ5=>R"<GQ'9=6R^>Q5.EVXI-./W/=K3(OK')>M5*.=?IV
MRG\AX(M\(E+=*W>:^B;-5;TV![J?,,Q*>S?)AWF2V!4<4!P8=J7,3ME2RNHP
M#L((^ AAXV]UG20W2[.UJ ]Z-A2?U>DT-NH)D79@C:L><JJLT\3QYU%?L=LD
MC:]CCP849NF:TA 2KB#'O3QDL1[-^"G+U /"K+36^GTYV#+4==&)"9M!$R[[
M5S3$&7(B_!&0=X+]('498/E^0[W[OXIFRYRZIM42E:IFU\QKD.TW5IBRJGP(
M? (WG]#D1F!AUA:5#D.]B.5PJ)M9V:^5R@PC(!K7BVYDS<H@*'4W$F4<2"WF
M2HLB_=EYI2 =8^P21FWQIBBE(]UECP@\+TF-,+*4930#;]',!H*$3PVHL:'3
M@.U2E>*3:GXY*VXZ08!#L#$C^ZD,6\;>9=L%1W$_V20GTL!A39:^"RJS&-W)
M:JV5;FA__P/CCE3;BI(5^3[5:A ]WLI[;Z^RTU#QQN*H5";<\C+K;E**"J2F
M2":F #$HZ5P12#D>.+>A+@(JYH!N?L9#&(V BTW4JK^J::WS.]TMYVH%+1?<
M5C(;:TU$,7UG!0LM$OS\S*6Y[LKSP6'G6A$<(R9<*WM#VOLIXZ4PS(JZH_#U
M,Q-5-XC\N"<!,5UX1B>P;*6]T"K?H'CEE,X[!)8ZYMHY5#$48\?>31 'NOV<
M_)B@'AZCE-B_1*&UBTH5PA 7?1M9"\ENCG[*7(V:[3A5Q'[!#4:[= ;B+*&Z
M622X6@UI<P^UQ]$JW,$IGU)J8FB79<4C(>]E+?&4M &XR?-*FBFL,S@\<I,,
M$]$GN&YR^]MY<N:UUAK,##WL@_*7J)$$=R#CD ]6H1CDLT@'K+GFYMCRNMC\
MLK">X?:K;;QT0[G[&5'NVYA07K8N>B,?Z6ZU-2&DI Z5[LX295!1&S+^2Z:Z
M4"G(2JC5.\FP#ZV.V)'VMOUQSZ@IB/5H__\U_// 0WZ!=?D;2D'(X_VM2RKJ
MAYH7!:[>4"_FLO?Z\?'^%UWTBE#HLTTH5(5"GWV?H="O<'.6X-Z/3X-?CJ].
M!Y>7P2]O!Q>#LS>.^[S;P>I_U&7 J_TGJH)5U])"43- 8IZI\I<V[MPMY#=)
MBK(2M17M(L0.?L;:=I^*_[_J'YP,@L/!R<EY_^CH^/2GOSW:?41_OSSO'ZJ_
M?^+<EEZF5Z"@C*L;?-_NGX%HKR[4,-C) HN%J=7 6QJ7]V@?%W $Y(S_N3H*
M#L]PUJ=_>_143YE^QHC+O("!YS.P'C&[T7UC&D_PXASL7R9I'IR#33:-PN X
M&\$)'?  ,-;CJXO?,D^U]3);>X;.-+SG]*J>W'=5>GS[C;@(OOK!%UC+P>+E
MZN6L8O(RDZ^Y8/4SH=D?D637VP--YT_7^HF^NO*KY_ KDBA"A,&G_>./MO9>
MFND_T?-?Y[]?@]C6WMU'^U?HM?U:>]I.GX^)'W\YD?"D24U?H=D]_U+ZG*N]
MZ"E^)PK3U[>K0!R>GET='PZ"LS?!X.^#B\/CRP'+PX?46OZ(.HHG/G9WGM3L
M:%%!WIR=7JWD*L"_<F!>^.S^6NQNW=<VJ#]F$*4!/3B3^GI6PM9>#\-QW0XY
MZJ3DL 0]8L2>E$[,^I_R3ZUNC5=SQZHUXZ72Q*:,OGK'%CE^DHE=6EOJ=:O&
M\51/H]09<CJQ3G6U4?%-#EZKZN6!5[ 9DW:,)](MM*]:QWY]"^7+G?V3'@B[
M!7<YE<H^F HC&3W4D7<+3@HSA\VV#?./O9=?JS_F'].@\YCEG@+@NWQN)2O]
MX3]?_.79L_7402SO$MW!+:&@NT:%O,_(AW^)"-/R59 7#\8'-P?_E0Y^8@/3
M;N+F D5M"4&4CHX]$56^3>CE,.N0(#*0>1JY^8;86\6J5Q:V Z7H/2J;6*3(
M-/J83.?3)5V(14YY-=.E^JX/NV84YA@=R\LFN?-E58'?E8!X"@("&X!B17O*
M7*3V"/4D=LHAL^H^V\H$ U.)JA@L20\R&9G6+L,XS>\^GUCY'6E9?*?_N?R?
MKS&E+[$97VJ4JWH:1R-\5EB3%"#N=HY^Z1\&?:G]>DI\94.$?S0BW&S&[WLS
MOJ* >\88K!'#CX%%'&>W<5GEA85LL(49XI@S5: U,C]+Y&>J1&N$W>@F*JWO
M0M?/"8ZH2=@\O8Z6%61&.;KWXNE3KI[.<*P'-DR_%*=>US'SOY?'/YWVK]Y?
M#+J=LS?!V[.3H\'%_VGOS!^S7C5'/O#TF0X1CC1 P/7B9;#BBJ[]SX,?\/&^
M06S 2DQ!N( _SQE9KE?8[? 2$=#Q"<O\4B?2M([/<BH/KAM1B>V'7,&#+^$(
MN.7GNP%?>O;W"C;]N DV?;U@T\-;VSK49(M!?//V78RY""^##'-$TD?[_4N4
M@.\&\-B;LXMW#ROYUI^6VIW?/)O&T["F6)/"3YXK1."5ZL7J%I\RR<6J"2$G
M.G/S7L25@GZ1+DR2IM7C9B<XR@D\/U>>*-5<5,<^N$KFSH, #S4![N)E_<PT
MN)Z2P]L+I!;\W#]Y/P@N!H>#XY\'1V'S)G.^M)5/9G)F*I4Z5<0ZBTIWF<V_
M\-89+['M%?:]QIX?=G?WSZ^"]:<E;!>SM:-9">Q1_>D1<;7E_N%'BO/5'+[/
MT;DL7SZ@<O.2V;X&AC1.I(6&B$64H%+PE*BW2H"VT[J2U\:#W'N?UIN2!3WY
MQ#=LL1,4BUIE5>\;F703XN:!)MOG=/27OV6Z7X1P'O@VV:SGCS#.^4V>Q:Y;
M](^PK,$T2M+ $*W/_1YX>)^;_%&V]3[&UF:]#['>+\+LT18?UXQQ^'L86+SY
M]R^TOBD)ZQ6!T@ZV-J>(DJ;?R/*^J;/XIB;K$8X2>E^:;#1LXH_FL=^,O*Q>
M++8'WE9>/-N;Z.*GK"]L<K(\FN1B;'!GJN6B U'^:SL0G?&_\E$\/C@[^@?A
MB-Y>O3O9__]02P,$%     @ RX-!6U.!<2_$"P  US(  !D   !E83 R-3DT
M-C0P,65X-2TQ7W-I;&\N:'1M[5MK<],Z&OZ>F?P';78/T\XD:2Z]0%LZD]("
MW5-*)@V'.9]V%%M)=+ M8\M)PZ_?YY7DV DIA4-@80=F:!-;>N]WJ:<OAZ^N
MSZJ5TY>7O0O\9O3O='@UO+X\.]VSO_%VS[T^/7]]\2>['?YY??FT-E:1/F;M
M5JS94(8B93=BS@8JY%'=/JBS6Y'(<8TV]O-=6MSI!@_D)#IFB9Q,]0G[7$ G
M+.3)1&(C+6W5SD[/SR[OIG(D-3MHMD_WSD%S']C*^/XV\$?1*(U/E@"'O?/K
M2_;L\OKZMM][=G7SXFFM53/?^[V+B_S[%R.=2U]/:6GKMQ,V4HDODH:G@H#'
MJ3AF^:>:4<WI<) CF(E$2X\'N22UBFM.?:?#"S9X_194WCRM[2])<HB."$_,
M?5]&DP9V';-NLQOKXIG1R3$[;#XYB#5$?/7J!;L=/'M:$W<'C?9_6JUV\Z]X
M4F.]Z^'36B&EX44)_2K*[A>B='"^7H.W4Q''//'K[%46!!++!]*;:I&P1SR,
M3]A+_-0J8E"A5?.6\'9;6.:]$V,1!$#6#_@'3@B,E/!C\(7:=*N^M;AHW9\J
M>5=G^2= :;<[#>C\8*L"ZK0[S<.#;O/Q4:N%=S+:@G2(F$8J/PA+$2SW^>N;
MX<K;,0]EL#A^B-B/()7(;;,QOSO=(] _,,'S^;R9.N,/C>DW/15N)GO/!+9O
M$32_$ESM[+6GU0@.U*ZS3JMSL*78_E%D_UIPR$*G;\[^N.JQRXL7O<'IWINS
M+:8BA#$9*-:?\B3D=785><VM03X\.F(W3?:6IU,$%@J%YRH+Q QFLSWJ><)3
MI4'Z\VO6W>]T#W],/1;_FP<RJIT-X$U0ZT!,9*H3KB6D<ZNY%J&(-,.7YRH)
MV6VC:_7]([)TPLK%UE]9JN5X43N[YKX$!![Y[ 5X"8BCXY^*@[>"3?E,,.YI
MX3.>HD[*HE0$B+2,O*5:*;L+V]%3P1X%_OM,G3Q38<RCQ:/$?-NM,PY"9MSG
M@)'$RBE:1O@:1<(SW^923QG!4.,Q2(PFB+@)2WE 3UBG_OC@J-[>[[(42,%8
M&=VM>91CJU:P'I$X!-!4HT2@_;3:455'292P&0\RP?[5:K:0>%F, &@ K[,1
M&H,$D(*7.$O2C,,\(0=:?(_Q[O"T6O'%6$:0WD@$:KYKK(&V]!.5QN [2VD9
M6UW59&^B0*3%XZE(!-55'H^EAI8^X!GJJS"U^B& H> 11):RB9R)R%$6DH3U
ME.MJQ4.R1 4 Y7M9(C599C]+O"E/!>M-$N%(-KR#37WRR85V"43A<S*-6Q&#
M9\HAG2<VB=39:&&8Y9#?I"S\:B670>S )BF3/H#*L00L%9F7*4R1ZPSZB/D$
M-&B2 ;@J:Z>_!%#H)A$!]$ HK6YD2JKRA"'&V!((PXMJQ=&3VX8UH6T%_7L\
MZGMX[7 J4Z9B&1D/2V%3QI6R))(H5GR8!%3@P0U](Y>EUR7B?283H]Z4A'(%
ME;+#5GMGM+MSL+LC=^DA3#T+G*$W?F_"\3=X<(&_SN8NAB1B)L6<P@CT "5!
MU=5*%CMMC]& J3GH_&8!LN@KRWWD>I^YVE'9;O%+\=O>R^C'/1@IK568ES$/
M%K ?MW:M9L<D2UM3WOOZT3^?'!X].5E?M=%*/A&W2DF7[3R7<)D;U63=;K?1
M.3H\/'B\"Q-"8.!!L&!CO/:-WJL5XT5%U"!%7][!0:.)<?X0KDB(UN.K?9Q[
M,&'_-X\RGBQ8IVN"R3[+(O3K; U^S]-DD>TG72Q##.4@WB>K6DD,*^N72'9D
MY 49M7F,0H"OO,S:/9Z[_$31> %+12H2Y"<Z#\(EZ)L%6'=HBDAG@A( QD74
MMP08=V1IYDWO4P;7!H*&H3&IX<P>^&0"&1(N![\JB:O;<N):Y0XYZ&^R=TXQ
MO\A4N?1V3XK>9G-?L^(('[O!+^?\#.<LV4J:Q7%@38O-IQ+&XJS'I$6VIJ:Z
M<TI8ANOLJA77VJU4+@.T(&R_LX_X?J^#+?&EUE02*CP4>5LY#:];R"_[^ [V
M\<GZ[)<&OH,&>H0>=;HIEJ)R7[/:;E"(MP$[+VZI:C9%O1K_TM1WT-3Y(N#S
M])=:?C"UH-]2048>L]3-N>*)3U\NT(H@>R7K6D.IYZM8V_RVTG=6*R;%%377
M1\#[B?2H*#)5I]9"?#;6>_M<QC,]58G\ +A[Y/WC!3[96EC<(42;>$ T^>AY
M(/"BW_Q4_*[?T[NN]*I+5N-$Q-R%'GJ&_$]LJK&EHUP:T&M%M1X-=8QL3,^6
MB E)P#79)[3LEP-\6P<P1;]5Q;(^I_$%->;X0/,:.09QFO@+18C<$OF\I$ 9
MH5UP=3U-FM!I^[ >AF9<I"DU!-04L1%/4;W1)*W<F#>WK=YO,LJX0BK-$C@2
M#V5D[+L8*' X1TCM'IGX1$29C$1$0S/X"%K38H $A$4_A!81WBV<M&EK -,/
M:++&/:GMS,J#TPN-MFB1 S.0L"P620JGL3O)]6EL1?O,R)%6%KU6FHU,E#$5
M<T8Z8@@4X)@'#H"G(N@E)+18DK\L@?@<F&/NI3)$Q5]G(H"7)RJ27MT._-Q$
M+6'Q5&GEJ7A17P:-,O5Y7%G21P^,@6(/(E23]5)3]R,2 I^F;H#.+XH1J#,K
M4*A-I+3=I)L]DF5*GT5*0Q.^B*E/CW2P8 *K1X%,IT3CC*QB49X8T9"(F1E1
MFO?#J9L?(>2E^,J7\5V-X2PT2BP<I+QJ)E*CHG),7ZYTF\9HCT"-9V%)B.&[
M3@.!Y1^-!GLN1> ?LSZ?B!. >I]1>PZ,K-'(#S<OKO[8Y*;MSH:0=TC/W(6'
M_-EYP+UWK-T\ !-(DM)'8-MX<<2#\$3RN7'5'"Z#M@UDCA+!WS5& N8.7F+#
M6QGHX0:@Q$Z9L'NF>RLH2P+<(PE:H?W,TUQJ[IT3V$$I4K6RDQV?PL%?<'G$
M0.N%[S-L-TG#N(69OU.8C/7'OFD<C<X[<M]W$V-RV7*187QQ)$3$_ PNF]<[
M=GY$T<G,C5.I!6)./EQRU45>6*,ZT>L553%R< =# S&3Q"O-OC*]=L!S,[A=
M#N_ %LTE1+12"R4B+[%,4E"&^Y@C[E#NLT-_UB\=.:!6VC %M\<JGU.C&02&
M#!#NFR&:VY;7;28W43=!\Q,C/9O>[=2O)(Q'24JLI7!4]2X/<:X0*/$XEQ#W
M2-#)E?0!C? (R&*<T2C6\$I;(Q4UH'8J D:!^#\XT7AKNS+H$!F3 GJ>=58*
MW=*I1R T73^B^@?:<5?7W)YUD3_+DH1 #@1,MQA^/V[\GI^<Y-.TM1;1R'IM
MH%JM%!-5&7WR>+#)P!9RC+J'M])H5IDJ:"Q!5N$UJ%@,0.<@UZ:,><6)\70Y
M@'9F5G0 YL1F(F?FA(Q$YK"::. KDZ.Y'Y*X* ZX$$'>X4!103I1MHUQU1"<
M0*5B2;^9%9JC)-^26ZW<NO.AHPV.9::,AN$L$+GMYX=,Y3XL/S^($Q5FP<1(
MW/B7E0F<W)Q8';2>;#BH^MG.W<4=U2XI]+$T:FY*L-!JF$T4(EU$H<X<M"Z8
MG7"8P@>JL\I"U/SI./=EZ@5<AH8IA7IL8K5($=VG#%&M+%1&*C:5*#HEF: \
M1FZ#K^"KF-G2&6T5/@8JMF6C,6>R%CZFT!#R!4724:*RR53G+D:RC99MM-E"
M"WF +:B<W; (NY4/<FWKD:O':6R97YOL-2"6SF'= D3J /6ZJ^'-T;U3:2HT
MY2HD(CY2,]OUSRD0&/LN+,$D/Z-HJ%Z&<> 2/@K<Q%K '&*J.X,Q8C2K<SSK
M1^3+@_#D&QR$?]T<8*NM_\HMX(?F /<8Z*;AP*&!]G#/O\2_3QL&PH1DF[N7
M?5W=7?&UG?G?IK!\7_BA041Y:7Y=D3UTT7);R&]?7O;[O<%%G;UZ<WU]=5-G
M@ZMG+X>7@_SN<.]5?_CZQMX=7J=P>W<JMW]9\8>,NC\JFZQE+EG;CZNF95O0
MK5]"?!#?$E.II:03TT;>5I;;V]6X4GI1OC)<:L1-E-K0A>=,4D?K?I8[VA7\
M_Q.Q[]$?IMB_5*$_:/DO4$L#!!0    ( ,N#05LZLY;[.@P  #$H   :
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M]P9'[ZZ/J=1&A!,D_/(4R>D._451_!,C^DND_P)02P,$%     @ RX-!6_X
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M*[E5FO=C:#]48_=(H<!QEDB&[#6-.DN8H4G1I2$31,0VI=JN:_-DY_6EH '
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M[V&U6_X'4$L! A0#%     @ RX-!6_<(A)H)'   WID  !4
M ( !     &5A,#(U.30V-"TX:U]S:6QO+FAT;5!+ 0(4 Q0    ( ,N#05L0
MHHK0DK   !VW P :              "  3P<  !E83 R-3DT-C0P,65X,3 M
M,5]S:6QO+FAT;5!+ 0(4 Q0    ( ,N#05M,-D-DM$4  +=R 0 9
M      "  0;-  !E83 R-3DT-C0P,65X-"TQ7W-I;&\N:'1M4$L! A0#%
M  @ RX-!6Q- L<"C1@  \'<! !D              ( !\1(! &5A,#(U.30V
M-# Q97@T+3)?<VEL;RYH=&U02P$"% ,4    " #+@T%;4X%Q+\0+  #7,@
M&0              @ '+60$ 96$P,C4Y-#8T,#%E>#4M,5]S:6QO+FAT;5!+
M 0(4 Q0    ( ,N#05LZLY;[.@P  #$H   :              "  <9E 0!E
M83 R-3DT-C0P,65X.3DM,5]S:6QO+FAT;5!+ 0(4 Q0    ( ,N#05N#+",S
MQ0H  ) D   :              "  3AR 0!E83 R-3DT-C0P,65X.3DM,E]S
M:6QO+FAT;5!+ 0(4 Q0    ( ,N#05O^ !]+)@,  .@+   1
M  "  35] 0!S:6QO+3(P,C4P.3(Y+GAS9%!+ 0(4 Q0    ( ,N#05NLK$&R
M_ H  '^&   5              "  8J  0!S:6QO+3(P,C4P.3(Y7VQA8BYX
M;6Q02P$"% ,4    " #+@T%;M.9EB%@'  #85P  %0              @ &Y
MBP$ <VEL;RTR,#(U,#DR.5]P<F4N>&UL4$L%!@     *  H M0(  $23 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>ea0259464-8k_silo_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="silo-20250929.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001514183</identifier>
        </entity>
        <period>
            <startDate>2025-09-29</startDate>
            <endDate>2025-09-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-29" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-29" id="Fact000004">0001514183</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-29" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-29" id="Fact000010">2025-09-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-29" id="Fact000011">Silo Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-29" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-29" id="Fact000013">001-41512</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-29" id="Fact000014">27-3046338</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-29" id="Fact000015">677 N. Washington Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-29" id="Fact000016">Sarasota</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-29" id="Fact000017">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-29" id="Fact000018">34236</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-29" id="Fact000019">718</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-29" id="Fact000020">400-9031</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-29" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-29" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-29" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-29" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-29" id="Fact000025">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-29" id="Fact000026">SILO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-29" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-29" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
